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It has been shown that prolonged systemic presence of a drug can cause a build
up of that drug in the skin. This drug ‘reservoir’, if properly understood, could
provide useful and important information about the recent drug-taking history of
a patient. In this thesis we create three mathematical models which combine to
explore the potential for a drug reservoir to form in the skin and be collected as
a method of monitoring compliance. The first model is used to characterise time-
dependent drug concentrations in plasma and tissue following a customisable drug
regimen. Outputs from this model provide boundary conditions for the second,
spatio-temporal model of drug build-up and concentration profile in the skin. This
then provides initial conditions for the final model which predicts the extraction.
These models are then used to identify the scenarios which have the greatest
potential for successfully monitoring patient compliance via the skin.
We focus in particular on drugs that are highly bound as this will restrict
their potential to move freely into the skin but which are lipophilic so that, in the
unbound form, they would demonstrate an affinity to the outer layers of the skin
(which are built around a lipid matrix). We highlight how this study might be
used to inform future experimental design and data collection in order to provide
relevant parameter estimates for reservoir formation and its potential to contribute
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Worldwide, non-compliance to drug regimens poses a significant challenge to
effective treatment strategies. A report by the World Health Organisation
estimated that only 50% of patients living with chronic illness in developed
countries adhere to prescribed treatment [1]. The level of non-compliance in
treatment of addiction is higher still [2]. In order to tackle the issue of non-
compliance, an effective method of monitoring occurrence of non-compliance is
necessary. There are two approaches to monitoring: ‘direct’ methods such as
blood and urine sampling, which are unable to detect poor long-term compliance
and ‘indirect’ methods such as questionnaires, pill counting, and self reporting,
which are easily manipulated by the patient [3]. The need for a more reliable
method of monitoring is therefore apparent.
Alternative drug monitoring methods via non-conventional biological fluids and
matrices are available, but less widely used due to practical difficulties [4, 5]. Drug
monitoring via keratinised matrices, such as hair and nails, are able to provide
information about history of medication, compliance, and drug abuse but can
usually only provide a binary result (positive/negative) and cannot test for more
recent drug use or current levels [5, 6, 7].
In this thesis we are interested in compliance monitoring via the skin. On entry
to the systemic circulation, a drug distributes into all of the tissues in the body
to varying extents. In general, this process is reversible as the tissue and blood
compartments are in dynamic equilibrium. In the case of the skin, differentiation
and death of skin cells means that some drug can be trapped in and amongst the
cells, potentially providing an archive of drug taking history of a patient.
The reservoir function of the skin is a recognised phenomenon in the field of
transdermal absorption [8]. A reservoir of drug in the skin was first identified for
the case of topically applied corticosteroids after a prolonged therapeutic effect was
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Figure 1-1: Schematic of reverse iontophoresis, where A+ represents an unspecified
positive ion.
observed [9, 10]. Presence of a reservoir in the skin has since been demonstrated
for many other drugs [8]. Moreover it has been shown, via tape stripping, that
the main site of this skin reservoir is the stratum corneum (SC), the layer of dead
cells at the surface of the skin [8, 9, 11].
Research on the presence of a reservoir in the SC is generally focused on formation
from an external source, specifically topically applied drugs and chemical exposure
[8]; drug that comes into contact with the skin surface enters the body via passive
diffusion. As only unbound drug diffuses the cause of a reservoir forming in the SC
is thought to be high keratin binding and slow desorption kinetics [12]. Binding
within the skin is most typical for lipophilic drugs with high molecular weight
[13, 14].
More recently, detection of a ‘reservoir’ of drug in the skin as a result of its systemic
presence has highlighted the potential of skin to act as a site for non-invasive
monitoring [15], both to measure systemic drug levels and to estimate historic
usage by exploiting the reservoir. The existence of such a reservoir has been
demonstrated for a number of molecules (including urea [16, 17], glucose [18], and
lithium [15]) by reverse iontophoresis.
Reverse iontophoresis is a blood sampling technique. Two electrodes are placed on
the skin of a patient where a small electric current is passed between them. The
current encourages the flow of ions and other molecules to the skin’s surface where
they can be collected and analysed. A schematic of reverse iontophoresis is given
in Figure 1-1 and the process is described in detail in Chapter 4. Iontophoresis
was developed as a drug delivery technique but due to its non-selective nature, as
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drug is delivered at one electrode, molecules are simultaneously pulled from the
skin and plasma at the other. It has therefore more recently also been utilised as
a sampling technique [19].
Reverse iontophoresis benefits from being non-invasive, resulting in a reduced risk
of infection and less associated pain. This offers the potential for increased patient
compliance. Moreover, reverse iontophoresis machines do not require trained
personnel to operate them and therefore offer the possibility for patients to use
them in the home. Indeed, in 2001 the FDA approved the use of the GlucoWatch
Biographer, a reverse iontophoresis device worn on the wrist which returned glucose
levels every 20 minutes to help with the management of diabetes [20]. However,
there were a number of issues with the watch [21] and so in 2006 when Cygnus
inc., the company who made the GlucoWatch, closed down, production ceased.
Reverse iontophoresis is still in development and a blood sample is required to
calibrate the results to the blood concentration of an individual patient. Research
on an internal standard is under way [22, 23]. Another perceived problem with
reverse iontophoresis is the initial lag time; the period of time between first starting
the machine and readings correlating with plasma concentrations. For this reason
it is advised that the electrical current should be applied for a minimum of 2
hours. Drug cannot instantly travel between the plasma and collection pad and so
there is an associated delay that is inherent. Studies for certain molecules report
“very high” extractions within the first hour of current application which reduce in
subsequent readings to reflect plasma concentration. These initial high readings
are thought to be the draining of a reservoir that has built up in the SC.
Lag time is still viewed as a hindrance, with information collected about the
reservoir often unused. It has been suggested that the initial readings may prove
useful in disease diagnosis [17] or compliance monitoring [19, 24] but this potential
has yet to be fully explored. If we can create a mechanistic model that predicts
reverse iontophoretic extraction resulting from a given dose regimen, then it is
possible that we will be able to interpret reverse iontophoretic extraction in the
context of compliance. Currently only one such mathematical model exists in a
paper by Paulley et al. [24] which mathematically models the accumulation and
extraction of a lithium reservoir in the SC. This model is based on results from
the study by Leboulanger et al. [15] in which reverse iontophoresis was performed
on bipolar patients chronically dosed with lithium. In this paper the authors
describe a two model system to determine the accumulation and extraction of a
lithium reservoir in the stratum corneum. The first of the two models is a two
compartment (blood serum and stratum corneum) model where drug enters the
SC directly from the serum compartment and is lost from the SC compartment
through a linear term describing skin renewal. The second model is an extension
to the first, incorporating a third compartment which represents the ‘collection
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pad’ for reverse iontophoresis. The paper showed that the amount of lithium
collected can be related to the amount of lithium administered and therefore
demonstrated the potential for reverse iontophoresis to determine medium term
(2 weeks) compliance. Lithium is in some respect the simplest case as it is not
metabolised, it doesn’t bind in the plasma or skin, and is a small, positively charged
ion meaning it is easily extracted via reverse iontophoresis.
The paper by Paulley et al. [24], along with evidence from Leboulanger et al
[25, 15], provided significant motivation for this thesis. Using Paulley et al. as
a starting point, complexities and other modelling techniques are built in from
the literature at each stage to create a more realistic and versatile modelling
approach to compliance monitoring via reverse iontophoresis. In particular, we
are interested in a drug that is metabolised within the body, is bound to molecules
within the body, and which is lipophilic. These choices reflect the properties of
many prescription drugs that are metabolised as well as excreted by the body and
which bind to proteins and other molecules within both the plasma and the tissue.
The drug buprenorphine which is used to treat opiate addiction where compliance
is an essential component of effective treatment, satisfies these three criteria and
so acts as a motivation for our choice. Buprenorphine is a semi-synthetic opioid
used in the treatment of opioid addiction with additional uses as a treatment for
chronic pain at lower doses. Buprenorphine is an ideal candidate for this type of
drug monitoring as it is often used for the treatment of heroin addiction as part of
a rehabilitation plan enforced by a court order. It is suitable as doses are regular,
usually daily, and it is an interesting case as characteristics of this drug such as
its metabolism, lipophilicity, and binding with plasma bring added complexities to
the modelling of reservoir formation. The chronic administration of buprenorphine
allows the reservoir to build up making it an ideal case study.
The ultimate aim of this project is to create a customisable model system that
takes a drug regimen and predicts systemic levels of that drug, along with the SC
drug reservoir size and resulting extraction reading. The model structure consists
of three sub-models: systemic concentration, drug reservoir formation in the skin,
and extraction of the reservoir, Figure 1-2.
1. Modelling Systemic Drug Concentration: After administration, the
drug is absorbed into the blood stream and transported around the body. The
amount of drug in the body varies according to distribution, metabolism and
excretion of the drug. In this section the amount of drug and its metabolite
in different areas of the body (blood, tissues) are modelled in order to estimate
drug levels at any given time for a user-specified drug regimen. The outputs from
this model provide boundary conditions for Model 2.
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Figure 1-2: The overall aim is to create three composite models which will be
linked together to create a model which predicts the expected reverse iontophoresis
reading for a given drug administration regimen and therefore interpret reverse
iontophoresis readings in the context of historical (order of days/weeks) drug
monitoring.
Many of the mechanisms and parameters in this model are motivated by our choice
of example drug, buprenorphine. However the model format is highly customisable
and could be adapted for a number of different drugs.
2. Formation of a drug reservoir in the skin: Our hypothesis is that drug
builds up in the skin over approximately a two week time period (after which time
surface skin is shed and drug is lost with it). We create a spatial model of the skin
using the output from Model 1 as the boundary conditions at the base of the skin.
We use this to relate skin reservoir size to the amount of drug administered. This
is a spatial model and the output of this model provides the initial conditions for
Model 3.
3. Extraction of the reservoir: We consider two extraction techniques; reverse
iontophoresis and tape stripping which are described in detail in Chapters 4 and
6 respectively. Reverse iontophoretic extraction is modelled using spatial and
compartmental modelling through use of PDEs and ODEs.
It should be noted that whilst Model 1 feeds into Model 2, the converse is not true.
We assume that any drug which enters the skin is not reabsorbed into the blood.
Model 2 provides initial conditions for Model 3 which describes the extraction of
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this reservoir via reverse iontophoresis and later tape stripping. We assume that
active drug is administered and it is the administered drug that we are interested
in modelling. A single daily dose is administered in the fully compliant case. The
separation of the overall system is reasonable as each stage takes place on a different
timescale; moreover, it allows for the potential for each stage to be verified using
experimental data.
We conclude with observations about the potential to exploit the SC reservoir as a
mechanism for non-invasive drug monitoring and determine important parameters
and drug properties that impact on this potential.
As we are combining three distinct models that draw on quite disparate literature,
the literature review for each model will appear towards the beginning of the
respective chapter to provide foundation and context for the work that follows.
Thesis outline
Chapter 2: Modelling Systemic Drug Concentration This chapter begins
by describing current approaches to modelling systemic/plasma concentrations
of a drug. A full description of characteristics of the chosen case study drug,
buprenorphine, is then provided. A model to describe buprenorphine concentration
in the plasma and tissues is developed and compared with data from the literature.
The final model in this chapter is referred to as ‘Model 1’ throughout the thesis.
Chapter 3: Formation of a Drug Reservoir in Skin In this chapter we
begin by describing the anatomy of the skin and factors that may affect reservoir
formation. We review relevant literature, with a focus on literature on passive
drug delivery, as many of the associated processes are similar. We then create a
spatial model for the formation of a drug reservoir in the SC. Boundary conditions
for this model are set up to accept output from Model 1 from Chapter 2, however,
combination of the two models is delayed until Chapter 5. The final model in this
chapter is referred to as ‘Model 2’ throughout the thesis.
Chapter 4: Reverse iontophoresis We begin by describing the process of
reverse iontophoresis and the theory and mechanisms involved. We review relevant
literature, drawing largely on iontophoretic drug delivery with a focus on model
framework and the potential to convert to the case of reverse iontophoresis. We
then go on to create a spatial model for reverse iontophoresis extraction of both
reservoir and plasma concentrations. The final model in this chapter is referred to
as ‘Model 3’ throughout the thesis.
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Chapter 5: Model Combination In this chapter we combine Models 1 - 3
from Chapters 2 - 4 focusing on the impact of chosen parameters and potential for
detecting compliance.
Chapter 6: Tape stripping Finally we explore the possibility of verifying/
supporting findings from reverse iontophoresis using the tape stripping technique.
Chapter 7: Conclusions In this chapter we summarise key findings from each






In this chapter we seek to create the first of our three models (Figure 2-1). The
purpose of this model is to predict the fluctuating in-body concentrations for a
specified administered drug dose in order to provide boundary conditions for Model
2, the formation of the drug reservoir in the skin.
We begin by reviewing the methods and approaches for modelling systemic
concentrations used in the literature. We then look at the characteristics of
our exemplar drug, buprenorphine, in order to identify key traits that need to
be accounted for in the model. We build our model starting with the simplest
approach, building in complexities to make the model more realistic.
Note the concluding model in this chapter combined with work in Chapter 3 form
the basis of the published paper [26].
In this chapter we focus on compartmental ODE models to describe processes
within the human body. Compartmental models are based on the principle of
conservation of matter; in our case this is the drug. All drug in the system must
be accounted for whether that be by movement from one region (compartment)
to another, or by metabolism or excretion of the drug. In mathematics a
compartmental model refers broadly to the use of a system of homogeneous well
mixed compartments, also known as ‘lumped parameter models’. They simplify the
behaviours of a spatially distributed physical model into discrete ‘compartments’
in which entities being modelled are assumed to be uniformly distributed.
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Figure 2-1: The overall aim is to create three composite models which will be
linked together to create a model which predicts the expected reverse ionotphoresis
reading for a given drug administration regimen and therefore interpret reverse
iontophoresis readings in the context of historical (order of days/weeks) drug
monitoring. The first model, for the systemic concentration, is the focus of this
chapter.
In pharmacology, however, the term compartmental model often refers specifically
to conventional pharmacokinetic (PK) models. In PK models, empirically obtained
in vivo concentration profile data is ‘fitted’ to a compartmental model consisting
of a ‘central’ and sometimes one or more ‘peripheral’ compartments. The central
compartment usually refers to the plasma or dosing site; peripheral compartments
are added to help the model better fit the data. The site of action and site of
elimination for a drug can be located in the central or peripheral compartments
depending on properties of the drug. This approach is phenomenological;
compartment volumes often take values that would be unrealistic in the human
body and don’t reflect physiological spaces. PK models are used as a way of
describing and comparing drugs to give some idea of how the drug will behave to
inform optimal dosing procedures and toxicity risk. As the model is created using
a concentration profile, the concentration profile can’t be predicted a priori using
this type of model. Due to the way the compartments are defined the model cannot
necessarily provide predictions such as concentration in a given tissue either.
More recently there has been a move towards more complicated physiologically
based pharmacokinetic models (PBPK) which take a mechanistic approach,
modelling each component of the body relevant to the passage of a given drug [27].
These are still compartmental models in the mathematical sense but should not
9
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be confused with the conventional PK models. In 1937 Teorell devised a model for
which he has now been referred to as ‘the father of pharmacokinetics’ [27, 28]. In
this model, the human body was simplified into compartments, each representing
a different organ or functional region of the body, Figure 2-2. Processes acting
within and between these compartments were described by a set of differential
equations allowing the prediction of the time course for a drug in the body. This
model was a precursor to today’s PBPK models which incorporate species and
chemical specific information to simulate the absorption, distribution, metabolism
and excretion of compounds in the body. An increase in computing power and an
emphasis on numerical rather than analytical methods has allowed the inclusion
of many complexities, causing a rise in the application of PBPK modelling to
drug development. This, combined with in vitro-in vivo extrapolation (IVIVE)
and statistical techniques to account for population variability, has resulted in the
creation of software such as Simcyp and GastroPlus, in which virtual drug trials
can be simulated. Software and models such as these are being utilised at all
stages of drug development from study design and justification [29] to regulatory
procedure [30].
The benefits of PBPK modelling are that, as any relevant information on a drug
can be incorporated, models can be used to predict the effects of multiple factors
which have not been combined experimentally: PBPK models are also intuitive
and therefore can be interpreted and understood by non-clinicians. Tools such as
this, however, require a great many experimentally determined parameters which
are not trivially obtained. A study by Zhao et al. [30] concluded that several
in vivo and in vitro studies appear to be indispensable to determine vital system
parameters and these require expertise, time and expense.
Our objective is to create a model that describes the movement of a drug within
the body which could be used to reasonably convert a given dosing regimen to an
in-body concentration profile that can be used in the wider model system (Figure
1-2). We follow the principle of Occam’s razor to create a model that is as simple
as possible whilst still providing the information that we require. To do this we
will begin our modelling by looking at the simplest case scenario, building on the
work of Paulley et al [24].
In the paper by Paulley et al. [24] the change in in-body concentration of lithium
is described by a single compartment representing the serum concentration with
exponential decay. This is suitable for lithium as it doesn’t bind to proteins in the
body and displays one-compartment pharmacokinetics. When dealing with more
complex drug compounds we need to extend this approach to obtain a realistic
plasma profile.
10
CHAPTER 2. MODELLING SYSTEMIC DRUG CONCENTRATION
Figure 2-2: The original scheme used by Teorell via [27] .
11
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We use buprenorphine as an exemplar drug to motivate our modelling choices and
hence we describe the pharmacokinetic processes in terms of buprenorphine. These
concepts are applicable to many different drugs.
2.2 Buprenorphine ADME
ADME stands for absorption, distribution, metabolism and excretion. These four
aspects describe the disposition of a drug within the body and determine the
exposure to the tissues.
2.2.1 Administration
Buprenorphine is administered via a number of routes: sub-lingual (a tablet or
liquid beneath the tongue), intramuscular (injected directly into muscle) and
subcutaneous (injected just beneath the skin). As the eventual focus of this project
will be on movement of drugs such as buprenorphine and its metabolites into the
skin, the subcutaneous administration route will not be considered due to the
complication of potential diffusion into the epidermis on administration.
It is common for buprenorphine to be administered sub-lingually as this does not
require a trained professional (unlike intramuscular or subcutaneous administra-
tion). As a result there is more data available for buprenorphine administered
via the sub-lingual route and so the preliminary model will be created with this
administration route in mind.
2.2.2 Absorption
Bioavailability is defined to be the fraction of an administered dose that reaches
the systemic circulation. Bioavailability of buprenorphine following intramuscular,
subcutaneous and sub-lingual administration is similar (dependent on dose,
individual and length of time retained in mouth for sub-lingual).
Sub-lingual dosing of buprenorphine has an estimated bioavailability of 50% i.e.
50% of that dose enters systemic circulation intact and is carried around the body
in the plasma. The mean time to maximum plasma concentration following sub-
lingual administration is variable, ranging from 40 minutes to 3.5 hours [31].
12
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2.2.3 Distribution
The rate and extent of distribution of any drug in the body varies depending on
the binding of drug to plasma proteins, blood perfusion of a given tissue, and
the binding of the drug within the tissue, which is largely dependent on drug
lipophilicity, pH and local membrane permeability.
The volume of distribution of a drug is the theoretical volume that would need
to be occupied at blood plasma concentration to account for the total amount
of drug in the body. Buprenorphine has a high volume of distribution which
implies it does not mainly reside in the blood. Volume of distribution however,
does not give information about a specific drug distribution; whether the drug is
stored in fat, highly bound to specific tissues or remains in the extracellular fluid.
Buprenorphine is a lipophilic drug and is therefore more likely to be found in fatty
tissues [32].
2.2.4 Metabolism
In the liver, buprenorphine is metabolised via N-dealkylation by CYP3A4 enzymes
into norbuprenorphine. This metabolism process can be described by Michaelis-
Menten kinetics.
Buprenorphine and norbuprenorphine also undergo ‘glucuronidation’ in the liver
resulting in two further metabolites: conjugated buprenorphine and conjugated
norbuprenorphine respectively. Conjugates of buprenorphine and norbupren-
orphine are not tested for routinely, consequently there is limited data for these
compounds. For this reason emphasis is put on the amount of unconjugated
buprenorphine and norbuprenorphine in the body.
2.2.5 Michaelis-Menten Kinetics
Metabolism Reaction N-dealkylation of buprenorphine in humans occurs in
the liver via the CYP3A4 isozyme of the P450 enzyme system. The responsible
enzyme acts as a catalyst, meaning it enables, but is not consumed by, the reaction.
The enzyme attaches to the substrate (in this case buprenorphine) to form a
complex; this part of the reaction is reversible. The complex then either breaks
down or goes on to produce the product (norbuprenorphine), the original enzyme
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which can be converted to the system of non-linear ordinary differential equations
dB
dt
=− k1BE + k−1C, (2.2a)
dC
dt




where B, E, C and N denote the concentration (amount/volume) of buprenorphine,
enzyme (P450 3A4), complex and norbuprenorphine respectively, and k1, k−1 and
k2 denote the rates of reactions as depicted in equation (2.1).
As this reaction is being considered in a fixed volume, we have
E + C = E0, (2.3a)
B + C +N = B0, (2.3b)
where E0 and B0 are constants.
Quasi steady-state approximation The quasi steady-state approximation is
based on the assumption that concentration of the intermediate complex does not
change in the time scale of product formation, which gives dCdt ≈ 0. Using this and
substituting (2.3a) into (2.2b) we have
k1B(E0 − C) = (k−1 + k2)C, (2.4)
=⇒ C = k1BE0










The parameter km is known as the Michaelis constant which is the concentration
of substrate when the reaction rate is at half of its maximum value.
Substituting the above expression for C into (2.2a) and rearranging gives
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where Vmax = k2E0 is the maximum velocity or maximum reaction rate at
saturating substrate concentrations.
2.2.6 Excretion
Buprenorphine and its metabolites are mainly excreted via the faeces with 10-30%
of a dose excreted in the urine. Dose excreted via the urine is primarily composed of
conjugated metabolites [33, 34] whereas in the faeces almost all buprenorphine and
norbuprenorphine appear in their free forms [31]. The assay techniques employed,
however, mean most studies describe the total buprenorphine or norbuprenorphine
concentrations “as they include pretreatment of urine with a beta glucuronidase
to remove glucurinide conjugates from metabolites’ [33]. A comprehensive review
compiled by Elkader and Sproule in 2005 [31] reports studies where the mean
half-life of buprenorphine ranges between 3 and 44 hours; discrepancies in half-life
estimates are assumed to be due to sensitivity of assay techniques when lower doses
are administered.
2.3 One Compartment Single Dose Model
Following the model structure from Paulley et al. [24] as the simplest scenario, we
consider systemic concentrations to be described using a single homogeneous, well
mixed compartment. Then, using the principle of conservation of matter, we obtain
the following word equations for buprenorphine (bup) and norbuprenorphine
(norbup) in the body:
Bup in whole body at time t+ δt = bup in body at time t− bup metabolised
into norbup in[t, t+ δt]− bup excreted in [t, t+ δt] ,
Norbup in whole body at time t+ δt = norbup in body at time t + bup
metabolised into norbup in[t, t+ δt]−norbup excreted in [t, t+ δt].
15
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Figure 2-3: Demonstration of model (2.6): concentration of buprenorphine and
norbuprenorphine in the body against time with Michaelis-Menten metabolism
kinetics and a linear excretion rate. Using ODE45 in MATLAB with eB =
0.5, eN = 0.5, Vmax = 1 and km = 0.5
Metabolism of buprenorphine to norbuprenorphine is described by Michaelis-
Menten kinetics equation (2.4) whilst excretion is first order.
In this first simple model for a single dose, that dose provides the initial condition
for the model equation scaled by its bioavailability.













where B(t) and N(t) are the concentrations of buprenorphine and norbupren-
orphine in systemic circulation at time t respectively. The parameters eB and
eN are the constant excretion rates for buprenorphine and norbuprenorphine




where α is the bioavailability and D is the dose.
The predicted profile for the one compartment model of buprenorphine and
norbuprenorphine, equation (2.6), is given in Figure 2-3.
16
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2.4 Multi-compartmental Multi-Dose Model
In the model described in Section 2.3 the body was treated as a single homogeneous
compartment. As already mentioned in Subsection 2.2.3, buprenorphine does not
mainly reside in the plasma and so we separate the body into two compartments:
plasma and tissue. The tissue compartment represents the non-blood compartment
of the body ı.e. all the soft tissues, muscles, and organs. We use ‘plasma’ instead
of whole blood as values for drug concentrations available in the literature are
typically given in terms of plasma.
2.4.1 The Model
It is important to note that only ‘free’ or unbound drug is able to diffuse through
membranes from plasma to tissues. Buprenorphine is a highly bound drug [31]; at
equilibrium only 4% of the drug in plasma remains unbound to plasma proteins
[35]. Buprenorphine binds mainly to α-globulin and β-globulin fractions. Since
other drugs bind to albumin there is little risk of competition for binding sites
[36, 37] which means we do not need to consider interaction between buprenorphine
and other drug molecules.
Taking binding into account, the compartmental model contains 8 state variables.
These consist of buprenorphine and norbuprenorphine in a bound and unbound
state, both in the plasma and in the tissues.
Figure 2-4 shows a schematic of this new model iteration. In the following sections
the terms describing the processes in this schematic are derived.
2.4.1.1 Amount vs. concentration
From this point onwards we will be dealing with concentrations (amount per
volume) of buprenorphine and norbuprenorphine. This is because a number
of parameters and mechanisms defined in the literature are dependent on
concentration differences (movement into the tissue for example). It is important
to make this distinction here as we are now dealing with separate compartments
with different volumes. The molar mass of a substance is the mass (in grams) of
one mole (avagadro’s number of particles) of a substance. The amount (number
of moles) of a substance can therefore be determined from the mass by dividing
through by molar mass.
17






Figure 2-4: Schematic demonstrating the movement of buprenorphine (arrows)
and norbuprenorphine (dashed arrows) in the body.
Buprenorphine enters the body in the plasma and is initially unbound.
Nomenclature
Labelling of drug in different regions of the body obeys the following format
from this point onwards
P (t) concentration (amount/volume) of a drug in the Plasma at time
t,
T (t) concentration (amount/volume) of a drug in the Tissue at time t,
Subscripts B,N, u, b denote the drug species Buprenorphine or
Norbuprenorphine and whether the drug is unbound or bound
respectively,
TBu therefore stands for the concentration of buprenorphine that is unbound
in the tissue.
First consider the unbound buprenorphine (bup) in plasma. Movement into and
out of this region is tracked as follows:
18
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Change in unbound
bup in plasma (over
time)
=− net binding








− bup excreted + administered
bup.
Using this equation structure we write the full system of model equations. The
mechanisms for each term are described in the following subsections.
2.4.1.2 (Net) Binding
Binding in the plasma is a reversible process where, at equilibrium, unbound drug
will be a fraction, fup, of the total drug in the plasma, (PBu + PBb). We assume
that the rate at which this equilibrium is approached is directly proportional to
the difference between the amount of unbound drug at time t, PBu(t), and the
amount that will be unbound at equilibrium, fup(PBu + PBb). This gives rise to a
binding rate
rB(PBu − fup(PBu + PBb)),
where rB is a positive rate constant. The effect of this term on the amount of
unbound drug will be positive if PBu is below its equilibrium level and negative if
above.
2.4.1.3 (Net) Movement into tissue
Again, this process is reversible. As an approximation, the distribution of a drug
between tissues and plasma can be estimated using the log10 P (log partition
coefficient) or log10D (log distribution coefficient) which are the logs of the ratio
of concentrations of a compound in a mixture of two immiscible phases, usually
octanol and water, at equilibrium. The partition coefficient usually refers to the
ratio of un-ionised species whereas the distribution coefficient refers to all species
(ionised plus un-ionised). This is often taken as an approximation of the ratio
of concentrations between fat and plasma. Only unbound drug moves between
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where kp = 10
log10D i.e. kp represents the ratio between concentration of
buprenorphine in tissue and plasma at equilibrium.
The parameter sB is the rate at which this equilibrium is reached and is dependent
on a number of factors such as blood flow to tissues and partitioning coefficients.
2.4.1.4 Metabolism
Metabolism of buprenorphine to norbuprenorphine is governed by Michaelis-
Menten kinetics and the same term is used as in the initial model; derived in
Subsection 2.2.5. Only unbound drug in the plasma is metabolised, hence we




where Vmax and km are the maximal velocity and Michaelis constant, respectively.
2.4.1.5 Excretion
Excretion is described by the first order removal rate
eBPBu,
where eB is the excretion rate.
2.4.1.6 Multiple dose




as used in the model by Paulley et al. [24] for a repeat lithium dose. For simplicity,
on administration, the dose is assumed to be distributed homogeneously in the
plasma. The parameter δ is the ‘size’ of the dose that arrives in the body, calculated
as the product of the mass of the dose and the bioavailability, and converted to
molar concentration by dividing through by molar mass and plasma volume. The
dissolution/absorption rate constant for the given route of administration is given
by k. This reflects that drug not given intravenously will not all arrive in the body
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immediately. Doses are administered at the times Ti where N is the number of
doses administered [24, 38]. Note that
ˆ ∞
Ti
δk exp(−k(t− i))dt = δ
which means that the full dose does eventually reach the plasma.
2.4.1.7 Volume adjustment between compartments
We assume bound and unbound drug occupy the same volume within compart-
ments. We cannot, however, assume that volume between compartments is the





This ensures that the conservation of mass is maintained as drug moves between
compartments.
2.4.1.8 Model equations
Combining these processes gives an equation to describe the change in unbound
buprenorphine in the plasma over time,
dPBu
dt









Using this same technique we can write equations to describe the change in
concentration of burpenorphine and norbuprenorphine in all four regions of Figure
2.4.
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dPBu
dt











δk exp(−k(t− i)), (2.8a)
dPBb
dt








TBu)− tB(TBu − fut(TBb + TBu)), (2.8c)
dTBb
dt



























− tN (TNu − fNut(TNb + TNu)), (2.8g)
dTNb
dt
=tN (TNu − fNut(TNb + TNu)). (2.8h)
Parameter definitions for two compartment model
rB the rate at which bup binds to protein in the plasma
sB the rate at which bup perfuses into the tissues from plasma
tB the rate at which bup binds to protein in the tissue
Vp total volume of the plasma
Vt total volume of tissue
eB the rate at which bup is excreted from the body
rN the rate at which norbup binds to protein in the plasma
sN the rate at which norbup perfusses into the tissues from plasma
tN the rate at which norbup binds to protein in the tissue
eN the rate at which norbup is excreted from the body
fup the fraction of bup in plasma which is unbound
kp a measure of relative binding between plasma and tissue for bup (ratio of
concentrations at equilibrium)
Vmax the ‘maximum velocity’, as defined in Section 2.2.5
km the Michaelis rate constant
fut the fraction of bup in tissue which is unbound
fNup the fraction of norbup in plasma which is unbound
kNp the relative binding between plasma and tissue for norbup
fNut the fraction of norbup in tissue which is unbound
22
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Note: presence of B or N in the subscript of a term denotes the term relating
specifically to buprenorphine or norbuprenorphine respectively.
2.4.2 Reducing the number of equations
As the binding of buprenorphine in the plasma happens on a shorter timescale when
compared with other processes in the system, such as metabolism and excretion,
it is reasonable to assume that at any given time the concentration of bound bup
in the plasma can be found directly from the total bup in the plasma as follows:
PBb = (1− fup)(PBu + PBb),
PBu = fup(PBu + PBb).
Using these expressions, (2.8a) and (2.8b) can be combined to give an equation for
the change in total drug in the plasma over time,
dPB
dt









PB = PBu + PBb = total buprenorphine in plasma.





where TBu is the unbound buprenorphine in the tissue and PNu and TNu are the
unbound norbuprenorphine in the plasma and tissue respectively. We then obtain
the reduced model system.
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2.4.3 Parameter estimates from the literature
Parameters such as Vmax and km are related to Michaelis-Menten metabolism by
enzymes in the liver. They are measured directly from liver samples in vitro and
can be upscaled/converted for whole body use.
Many of the other parameters have not or cannot be directly observed experiment-
ally such as kp, ‘the ratio of concentrations of buprenorphine between tissue and
plasma at equilibrium’. Tissue is a term used here to refer to the entire group
of tissues in the body in which bup distributes. Therefore this would need to be
taken as a weighted average across all tissues, data which is not available for any
tissues. Values for this term therefore must be inferred from other information
we know about the drug such as the logP value which is the ratio between the
concentrations of a substance in octanol and water at equilibrium.
Table 2.1 lists parameters and their estimates along with calculations and
appropriate data sources.
From Table 2.1, we see that bup is much more likely to reside in tissue than
norbup is (as determined by the value of logP for each). This, combined with
the lack of data available for norbup in the literature, leads us to restrict our
model to consider the dynamics of bup only. Moreover norbup is at much lower
levels than bup in the body and so we do not expect to detect more norbup in
the skin. Metabolism of buprenorphine to norbuprenorphine is irreversible and
so removal of the norbuprenorphine model does not impact on our predictions for
buprenorphine.
Many of the parameters we have are uncertain. In some cases parameters have
been upscaled from in vitro studies (Vmax, km), some have been inferred from
characteristics of buprenorphine (kp inferred from bup lipophilicity) and others
have been taken from predictions or estimations from in vivo data in various studies
24
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(eb, bioavailability). Next we take into account variability in parameter estimates
and set sensible ranges for the uncertain parameters.
2.4.4 Parameter fitting
Even though we have removed the need to estimate the parameters pertaining
to norbuprenorphine alone, there are still a number of unknown parameters in
our system; kp, sB, fut, (Vp, Vt). Though these parameters have a physiological
interpretation they are not measured directly in experiments and so their values
must be inferred from other measurements or other parameters that have been
estimated.
Vt and Vp are listed as unknown parameters here as the division of the body
into plasma and tissues alone is crude. Typical volumes for each tissue exist in
the literature, but the pharmacological compartmentalisation of the body is often
divided into ‘first’ (plasma) and ‘second’ (tissue) compartments without specifying
that this first compartment must be the plasma alone.
In this section we first discuss feasible parameter ranges and then go on to describe
the fitting process that we employed to obtain parameter estimates.
2.4.4.1 The unknown parameters
The parameter kp can be estimated using the logP or logD approach described
earlier. Buprenorphine is a lipophilic drug, we therefore use
kp = 10
logD = 103.93 = 8511
as an upper limit for our plasma tissue partition coefficient [32] with the assumption
that the plasma is approximated by water, and the ‘tissues’ are approximated by
octanol. Alternatively the fraction of drug outside the plasma at steady state can




kp ≈ Vss−VpVp = 110.6 using Vss = 334.9 [45].
The parameter sB determines the rate at which an equilibrium between plasma
and tissue concentrations is reached. There are many factors that could affect
this value including blood flow and drug affinity for lipids. However as this is not
directly measured experimentally there is as yet no simple way to quantify it.
The fraction of buprenorphine in the tissue which is unbound is denoted fut. This
parameter is difficult to estimate as the term ‘tissue’ here is vague; a value for
tissue binding for buprenorphine has not been determined and it is likely that this
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value would vary depending on the tissue in question. The only certainty with this
value is that it lies between 0 and 1.




to reduce the number of parameters to fit. We also acknowledge that without
further distinguishing information we cannot conclude anything about kp or fut
independently from the other.
2.4.4.2 Data choice
The multiple dose model (2.9) describes bup concentration in tissues and plasma for
a repeated sub-lingual dose. We choose to use data for a single dose to estimate
the unknown parameters as a repeat dose would give a non-homogeneous ODE
resulting in a much more complicated solution. Additionally the data available in
the literature is more detailed for a single dose.
Initially, we fit the model to intravenous dose data so that errors in estimation
of parameters, such as bioavailability and absorption rate, do not influence the
estimation of other physiological parameters.
The data set chosen is from a study by Kuhlman et al. [45] in which 6 healthy
men were administered buprenorphine intravenously (1.2 mg) and blood plasma
samples were taken for up to 96 hours.
2.4.4.3 Initial conditions
Intravenous administration involves injecting the whole dose directly into the blood
stream. This gives a bioavailability of 100%. Therefore, assuming the dose is
distributed instantaneously and evenly in the plasma we can calculate the initial
plasma concentration from the dose as follows:
PB(0) =
dose in mg× 103
molar mass× Vp =
1.2mg × 103
467.64× 3.15 = 0.814µmol/L. (2.10)
2.4.4.4 Linearising
The only non-linear term in equation (2.9) is the metabolism. For a dose of 1.2mg
it is clear that even at the maximum (initial) plasma concentration we find that
27
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As we are not actually fitting metabolism parameters (Vmax and km are already
known) the values obtained for sB and σ, relating to linear processes, should be
applicable for higher doses.
Our linearised model for a single IV dose is then
dPB
dt








(fupPB − σTB). (2.12)











 −sB fup −
Vmax fup
km







and B˙ denotes the time derivative of B. The analytic solution of the linear model




where vi are the eigenvectors and λi are the eigenvalues of A for i=1,2, dependent
on model parameters.
2.4.4.5 Fitting the model to data
The data points used are from a paper by Kuhlman et al. [45] in which six healthy
males were administered buprenorphine via the intraveneous (IV), sub-lingual and
buccal routes. As we know the form of the solution for an IV dose, equation (2.15),
we use the IV dosage data from this study. We begin by fitting a biexponential
(X2(t)) to the Kuhlman data set [45] using the inbuilt function in MATLAB to
get
X2(t) = 0.1034e
−12.85t + 0.01166e−0.4587t (2.16)
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Figure 2-5: Biexponential fit to data for plasma concentration against time
for a 1.2mg IV dose of buprenorphine [45] to remove data ‘noise’. K2(t) =
0.1034e−12.85t + 0.01166e−0.4587t
(see Figure 2-5).
We then use the numerical values from (2.16) to find parameter values that appear
as components of vi and λi (2.15). We do this by performing a parameter sweep
across each of the ranges identified for the unknown parameters. For each set of
parameters in this sweep we calculate the root mean square of the relative error





for the sampling points i=1,...,N where Bp(ti) is the buprenorphine plasma
concentration predicted by our model for time points ti. We then select the
parameter set relating to the smallest calculated value of (2.17).
For a dose corresponding to an initial plasma concentration of 0.814 µmolL−1,






resulting in an error estimate between the model and ‘smooth’ data (X2(t),
equation (2.16)) of Erms=0.3538 and with the unsmoothed data of Erms=0.366.
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The main problem with the data fit appears to come from disparity between the
predicted and experimental initial plasma concentration (see Figure 2-6).
We test this theory by inputting initial condition of 0.081 µmolL−1 (ten times
smaller than the theoretical value of X2(0)) and again seeking the minimal value
of the function (2.17). The resulting error for the smoothed data (X2(t)) is then
0.0186 and for unsmoothed data is 0.0236 with σ=0.00694, sB=102h
−1. This is a
significant improvement (see Figure 2-7).
If regions of tissue are perfused at notably different rates we may expect a very
steep initial decay in plasma concentration as drug diffuses into the rapidly perfused
tissues, which would be consistent with the first data points without having to
change the initial concentration. Naturally with any substance, movement into
tissue will vary between tissues; depending on blood flow, fat content and other
physiological factors and properties of the substance.
It appears to be the case here that if tissue compartments were divided further
into ‘rapidly perfused’ and ‘slowly perfused’ ones, we may expect a very steep
inital decay in plasma concentration as drug diffuses into ‘rapidly perfused’ tissues.
This would be consistent with the first data points and the high, predicted initial
concentration. We would then expect a triexponential curve solution and a better
fit to the data should be obtained. This distribution mechanism is supported by
data for buprenorphine in vivo in [48, 49, 50, 51], all of which report a good fit for
a triexponential curve.
2.5 Three Compartment Model
We now introduce a third compartment to our model by dividing ‘tissues’ into
‘rapidly perfused tissues’ and ‘slowly perfused tissues’. The schematic for the
new model is given in Figure 2-8. The new model, given only for buprenorphine,
without loss of generality, comprises of six time-dependent state variables:
unbound drug concentration in plasma, Pu(t); bound drug concentration in plasma,
Pb(t); unbound drug concentration in rapidly perfused tissues, Qu(t); bound drug
concentration in rapidly perfused tissues, Qb(t); unbound drug concentration in
slowly perfused tissues, Ru(t) and bound drug concentration in slowly perfused
tissues, Rb(t) at time t. The model equations are built from conservation principles
as described for the two compartment model and are modified as detailed below.
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(a)
(b)
Figure 2-6: a) Two compartment model solution of plasma concentration after
a 1.2mg IV dose compared to in vivo data from [45]. Using data from Table
2.1 with σ=0.00694 and sB=102 (from equation (2.17)) , with initial conditions
P (0) = 0.814 (from 2.16). b) The same graph plotted on a log scale.
31
CHAPTER 2. MODELLING SYSTEMIC DRUG CONCENTRATION
(a)
(b)
Figure 2-7: a) Two compartment model solution of plasma concentration after
a 1.2mg IV dose (line) compared to in vivo data from [45](stars). Using data
from Table 2.1 with σ=0.00426 and sB=48.54 h
−1 (from 2.17) , I.C. P (0) =
0.081µmoll−1 (from equation (2.10)). b) The same graph plotted on a log scale.
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Unbound




















Figure 2-8: Schematic demonstrating the flow of drug within a simplified three
compartment body structure. Parameters ki (i = 1...6) are described in the text.
2.5.1 (Net) Movement into tissue
The term describing movement from plasma into tissues is adjusted to reflect the
division of the tissues into rapidly and slowly perfused tissue compartments. This
process is reversible. Only unbound drug moves between plasma and tissue which
we exploit to give the rate of movement into rapidly and slowly perfused tissue
from the plasma as
−k2(Pu − f2Qu)− k3(Pu − f3Ru).
The parameters k2, k3 are the rates at which movement occurs and are dependent
on a number of factors, such as blood flow to tissues and partitioning coefficients.
Tissues are assigned to rapidly perfused or slowly perfused tissue compartments
according to blood perfusion values given in [46]. It therefore follows that k2 > k3.
The remaining two parameters, f2 and f3 represent the ratio between concentration
of drug in plasma and rapidly perfused tissue; and plasma and slowly perfused
tissue, at equilibrium respectively. According to the allocation of tissues to each
compartment, slowly perfused tissues have a much higher fat percentage than
rapidly perfused tissues [46]. As we are considering a lipophilic drug we can also
expect f2 > f3 (higher affinity for fatty tissue).
The terms for binding, metabolism, excretion and repeated dosage are unchanged
other than some relabeling. Therefore, the change in concentration of unbound
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buprenorphine in plasma for our three compartment model is given by
dPu
dt






δk exp(−k(t− Ti)). (2.18)
Parameter definitions for three compartment model
k1 the rate at which bup binds to protein in the plasma
k2 the rate at which bup perfuses into the rapidly perfused tissues from plasma
k3 the rate at which bup perfuses into the slowly perfused tissues from plasma
k4 the rate at which bup is excreted from the body
k5 the rate at which bup binds to protein in the rapidly perfused tissue
k6 the rate at which bup binds to protein in the slowly perfused tissue
VQ/P ratio of volume of rapidly perfused tissue to volume of plasma
VR/P ratio of volume of slowly perfused tissue to volume of plasma
fup the fraction of bup in plasma which is unbound
f2 ratio of concentrations of unbound drug in plasma and rapidly perfused
tissue at equilibrium
f3 ratio of concentrations of unbound drug in plasma and slowly perfused tissue
at equilibrium
Vmax the ‘maximum velocity’, as defined in Section 2.2.5
km the Michaelis rate constant
fuQ the fraction of bup in rapidly perfused tissue which is unbound
fuR the fraction of bup in slowly perfused tissue which is unbound
Analogously, we can write equations to describe the change in concentration of
drug in all six regions and hence we obtain the full model system:
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dPu
dt






δk exp(−k(t− Ti)), (2.19a)
dPb
dt
=k1(Pu − fup(Pu + Pb)), (2.19b)
dQu
dt
=k2vQ/P (Pu − f2Qu)− k5(Qu − fuQ(Qu +Qb)), (2.19c)
dQb
dt
=k5(Qu − fuQ(Qu +Qb)), (2.19d)
dRu
dt
=k3vR/P (Pu − f3Ru)− k6(Ru − fuR(Ru +Rb)), (2.19e)
dRb
dt
=k6(Ru − fuR(Ru +Rb)). (2.19f)
The volumes of each compartment were calculated using tissue volume data from
[40] for a 70kg human. As we are still considering a 1.2mg dose, we again linearise
the metabolism term. Taking the same approach as in Subsection 2.4.2, we assume
that the binding in the plasma and both tissue compartments happens on a much
faster timescale than other processes and that in each compartment unbound drug
can be determined from total drug in that compartment as follows
Pu = fup(Pu + Pb),
Qu = fup(Qu +Qb),
Ru = fup(Ru +Rb).
Considering a single IV dose which is accounted for by the initial conditions, we
can therefore condense the system into three linear equations:
dP
dt






=k2vQ/P (fupP − f2fuQQ), (2.20b)
dR
dt
=k3vR/P (fupP − f3fuRR). (2.20c)
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These equations can then be written in the form







−k2 fup − k3 fup − Vmax fup
km
− k4 fup k2f2fuQ k3f3fuR
k2 fup vQ/P −k2 f2 fuQ vQ/P 0
k3 fup vR/P 0 −k3 f3 fuR vR/P
 .
(2.22)





Accordingly, we fit a triexponential to the data [45] to find a smooth data set,
shown in Figure 2-9
X3(t) = 0.0646e
−11.241t + 0.0186e−1.299t + 0.00456e−0.200t. (2.24)
We fit our 3 compartment model (2.19) to the smoothed data (2.24) by calculating
the error estimate, (2.17), for a range of parameter sets while seeking the minimum
value for the error.
The 3 compartment model fit with P (0) = 0.814µmoll−1 as calculated in (2.10) to
the Kuhlman data can be seen in Figure (2-10). The error for the 3 compartment
model against smoothed data (X3(t)) was 0.1292 and against unsmoothed data was
0.1416. The fit is also visually much improved from the two compartment model
and the additional compartment allows for the high initial plasma concentration.
A triexponential curve does fit the data well, as shown in Figure 2-9, but the fit
for the solution to our 3 compartment model (also a triexponential curve) is not as
good. This indicates that either some of the parameters that we fixed, Table 2.1,
do not exactly match the physiological traits for the individuals in the study by
Kuhlman et al. [45], that the division into rapidly and slowly perfused tissues could
be incorrect, or that the forced initial condition (2.10) is too high, perhaps due to
the time taken to inject the dose or an instant distribution into the extravascular
space or tissues that isn’t accounted for by the 3 compartment simplification of
the body.
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(a)
(b)
Figure 2-9: Triexponential fit to data for plasma concentration against time for a
1.2mg IV dose of buprenorphine [45] to remove data ‘noise’. Triexponential curve
given by X3(t) = 0.0646e
−11.241t + 0.0186e−1.299t + 0.00456e−0.200t.
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(a)
(b)
Figure 2-10: a) Three compartment model (2.19). Solution of plasma concentration
after a 1.2mg IV dose (line) compared to in vivo data (stars) from [45](stars). Using
data from Table 2.1 with f2fuQ = 5 × 10−4, f3fuR = 0.465 × 10−6, k2=2000 and
k3=550 (from (2.17)) , I.C. P (0) = 0.814µmoll
−1 (from (2.10)). b) The same
graph plotted on a log scale showing first 12 hours after dose.
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Total buprenorphine in plasma
Total buprenorphine in well perfused tissues
Total buprenorphine in poorly perfused tissues
Figure 2-11: Simulation of plasma and tissue concentration profiles for a daily drug
administration, using model (2.19) with parameter values as determined in section
2.5 and as given in Table 2.1.
Note If we change the initial plasma concentration to 0.087 (X3(0)) and fit for
k2, k3, f2fuQ, f3fuR using our parameter sweep method, k2 and k3 are both given
as 50h−1 and f2fuQ, f3fuR are both given as 0.009, i.e. a two compartment model
with similar parameters as predicted by our analytic two compartment fit. This
supports the need for a third compartment specifically to account for the initial
rapid drop in plasma concentration.
This fitting process has provided us with an estimate of k2, k3 and the products
f2fuQ,f3fuR to be used with the full non-linear system. Using these combined with
parameters described in Table 2.1 (which are estimates for buprenorphine taken
from the literature) we obtain concentration profiles for a repeated daily dose as
shown in Figure 2-11. We use the profile for poorly perfused tissues as input to
Model 2 where drug accumulates in the stratum corneum.
2.6 Conclusion
A model to describe systemic buprenorphine concentration following a repeated
daily dose has been developed. The model presented here extends the simple case of
a one compartment in-body model for lithium to the case of buprenorphine, where
the drug metabolism, binding and unbinding, and distribution into the tissues,
are considered. Buprenorphine is used as an exemplar drug to guide modelling
decisions and populate the model parameter values used in numerical simulations.
For buprenorphine, a significant improvement in fit to data between a two and a
three compartment model is observed. The fit to data could be further improved
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by adding additional compartments to reflect the different tissue groups in the
body more accurately. Should the appropriate data and mechanistic knowledge
for buprenorphine and specific tissues become available, then an increase in the
number of compartments to improve model- data fit may become beneficial.
We have created a highly customisable structure which provides an estimate for
drug levels in plasma and tissues for a given dosing regimen. The modelling
highlights the need for experimental work to obtain parameter estimates; if these
can be obtained the model could be usefully extended to reflect different tissue
regions. Of course, the model has limitations. It provides a very simplified
structure for drug distribution in the body with tissue predictions unable to be
verified due to lack of data. The model described gives predictions for a ‘typical’
70kg human. These predictions may be affected by inter-patient variability such as
age and ethnicity which could be incorporated by careful modification of ‘average’
model parameter estimates once such data sources are available.
We believe that our model approach is preferable to a classic PK model as
it attempts to predict real tissue concentration values directly using realistic
compartment volumes. Ideally a full PBPK model describing each functional
region of the body would be used, however, this requires a large number of
parameter values for which we have no data. We believe that the tissue predictions
provided by our model are sufficient to warrant the formulation of a three
compartment model. If more data were to become available this would be
accommodated by the model structure.
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Chapter 3
Formation of a Drug Reservoir
in Skin
3.1 Introduction
In this chapter we focus on the second of our three models, shown in Figure 3-1.
The purpose of this chapter is to identify key mechanisms and characteristics of
skin, and transport across it, to create a description of the formation of a drug
reservoir in the skin stemming from a systemic presence of that drug.
There is very little research available in the literature focused on the formation of
a drug reservoir in the skin from systemic concentrations. We therefore draw on
research and theories from drug delivery models and experiments to inform our
own model.
The reservoir function of the skin is a recognised phenomena in the field of
percutaneous absorption [8]. A reservoir in the skin was first identified for the
case of corticosteroids after a prolonged therapeutic effect was observed [9, 10].
Presence of a reservoir in the skin has since been demonstrated for many other
drugs [8]. Moreover it has been shown, via tape stripping, that the main site of
this skin reservoir is the stratum corneum (SC), the layer of dead cells at the skin
surface [8, 9, 11].
Research on the presence of a reservoir in the SC is generally focussed on formation
from an external source, specifically topically applied drugs and chemical exposure
[8]; drug that comes into contact with the skin surface enters the body via passive
diffusion. As only unbound drug diffuses, the cause of a reservoir forming in the SC
is thought to be high keratin binding and slow desorption kinetics [12]. Binding
within the skin is most typical for lipophilic drugs with high molecular weight
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Figure 3-1: The overall aim is to create three composite models which will be
linked together to create a model which predicts the expected reverse iontophoresis
reading for a given drug administration regimen and therefore interpret reverse
iontophoresis readings in the context of historical (order of days/weeks) drug
monitoring. The second model, for the formation of the drug reservoir in the
skin, is the focus of this chapter.
[13, 14]. We therefore intend to continue to focus on lipophilic drugs to guide our
modelling decisions.
In this chapter we first provide a description of the structure of human skin, before
going on to review models of reservoir formation and passive drug delivery in the
literature to explore the ways in which various complexities have been incorporated.
We also identify mechanisms which are considered important to include and
consider how these might be altered to suit a non-delivery model. We then
create a model for the formation of a reservoir in the SC. The inclusion of various
model features are then analysed and the effect of different boundary conditions
are considered. In Chapter 5 we combine the model for reservoir formation with
models for in-body concentration (Chapter 2) and extraction (Chapter 6).
3.2 Anatomical Structure of Human Skin
3.2.1 Introduction
Skin is the largest organ in the human body, making up approximately 10 - 20% of
an individual’s total mass [52, 53]. The purpose of the skin is manifold; it is a vital
barrier against infection, UV radiation and physical damage and it plays a key role
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Figure 3-2: Cross sectional diagram of human skin (adapted and redrawn from
[52])
in the regulation of temperature, electrolyte and fluid balance in the body; it is
also important for its sensory ability and vitamin D production. A cross sectional
diagram of human skin is given in Figure 3-2. There are two distinct layers of the
skin; the outermost epidermis and beneath that, the dermis. The interface joining
the dermis and epidermis is irregular; protrusions of the dermis, called papillae,
interlock with epidermal ridges of the stratum basal. Beneath the dermis lies the
hypodermis or subcutaneous tissue though this is not generally considered part of
the skin.
3.2.2 Dermis
The deepest layer of the skin is the dermis, usually 3-5mm thick [52, 53], containing
capillaries, nerves, sweat and sebaceous glands, hair follicles, and small arrector
pili (hair supporting) muscles embedded in a mucopolysaccharide gel. In terms
of transdermal movement, appendages such as hair follicles and sweat ducts may
have a key role to play as they provide an alternative route for some molecules
crossing the skin, the so called ‘shunt route’.
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3.2.2.1 Appendages
Hairs are found all over the body except the load bearing soles and palms and the
lips. On average there are 60 hairs/cm2 on any given area other than the head
which has substantially more at 600 hairs/cm2 [53]. These hairs, however, only
occupy a total body area fraction of 10-3 [54, 55]. Sweat glands occupy an area
fraction of 10-4, appearing as frequently as 100-200 per cm2 [54]. Despite the small
area that the appendages proportionally occupy, many hydrophilic solutes can
potentially permeate via the appendages at a much faster rate [56, 57] especially
when considering electrically assisted movement, for example iontophoresis [52, 58].
3.2.3 Epidermis
The epidermis is a multi-layered membrane covering the whole body, varying
in thickness between 0.06mm and 0.8mm. Keratinocytes make up 95% of the
epidermis, the remaining 5% are melanocytes, Langerhans and Merkel cells
[59]. The surface layer of the epidermis is the stratum corneum, a layer of
dead, keratinised cells providing the primary barrier to percutaneous penetration.
Beneath the stratum corneum is the viable epidermis which is itself a multi-layered
membrane, each layer representing different stages of cell differentiation. The layers
of the viable epidermis, starting from the deepest, are the stratum basale, stratum
spinosum and stratum granulosum. The process of cell differentiation from the
metabolically active cells of the stratum basale through to the stratum corneum
typically takes 14 days with cells remaining in the stratum corneum for a further 14
days before shedding [52, 53]. There are no blood vessels supplying the epidermis.
Nutrients are delivered to the living cells of the epidermis via diffusion from
underlying dermal capillaries through the stratum basale and metabolic products
of the active cells enter the circulatory system by diffusing in the opposite direction
[60].
3.2.3.1 Stratum Basale
Cells in the stratum basale or basal layer are metabolically active and are therefore
similar to those of other tissues in the body. Keratinocytes within the stratum
basale are the only cells in the epidermis undergoing cell division, making the
basal layer the primary source of cell renewal in the epidermis [60]. Cell division
in the stratum basale occurs via mitosis; a parent basal cell divides creating two
new cells, one cell remains attached to the basal layer whilst the other differentiates
towards the surface. The cells in the stratum basale are columnar and rest on the
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basal laminar at the dermal- epidermal interface. They contain protein laments
(tonofilaments) about 10nm in diameter.
3.2.3.2 Stratum Spinosum
As cells progress towards the surface layer of the skin, the number of tonofilaments
increase and group, forming tonofibrils [60]. In the stratum spinosum the cells
begin to change shape from cuboidal to pentagonal.
3.2.3.3 Stratum Granulosum
Above the stratum spinosum is the stratum granulosum, approximately 2-5 cell
layers thick [52, 53]. In this layer the keratinocytes begin to flatten and produce
keratin. Enzymes are contained in the stratum granulosum which break down
the viable cell nuclei and organelles. Lipid bilayers of the stratum granulosum
form rod-like structures known as lamellar granules or keratinosomes, characteristic
of this layer. These are membrane coating granules which, when fused with a
cell membrane, deposit lipid containing sheets into the intercellular space of the
stratum granulosum. These lipid sheets will later become the intercellular lipid
lamellae seen in the stratum corneum.
3.2.3.4 Stratum Corneum
Sometimes the stratum lucidum is described as a separate layer; a translucent
layer, observed most clearly in thicker portions of the skin, such as that on the
soles of the feet. Here the cell nucleus disintegrates, cells become flatter and
further keratinised. The stratum lucidum is, however, generally considered as the
lower layer of the stratum corneum. Although the stratum corneum is only 10-20
cell layers thick [52, 53, 59] it is key in the regulation of movement through the
epidermis, imposing the rate limiting step in the majority of transdermal processes.
The stratum corneum is composed of dead, flat, keratinised cells embedded in a
non-polar lipid matrix arranged as lamellar lipid layers. The structure of the
transverse cross section of the SC is usually referred to as ‘bricks and mortar’
where the corneocytes are represented by the bricks and the lipid by the mortar
[59, 61, 62, 63, 64]. Figure 3-3 shows this configuration. The exact displacement
between ‘bricks’ within cell layers is not known but many models that incorporate
this structure allow for different arrangements. The corneocytes are thought to be
approximately hexagonal in shape and the bricks and mortar arrangement can be
recreated by assuming corneocytes are arranged as regular hexagons when viewed
from the transverse direction [65].
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Figure 3-3: “Schematic transverse cross-section of corneocytes in the SC, commonly
referred to as a bricks and mortar arrangement. The bricks represent corneocytes
and the mortar the intercellular lipid. Bricks have mean length l and mean width
δ. The mean horizontal distance between adjacent corneocytes is µ and the mean
vertical separation distance is . The distance lL is the mean largest horizontal
distance from the centre of a lipid channel above a corneocyte to the centre of one
of the adjacent lipid channels. Finally, lS = l + µ− lL.” Taken from [64].
3.2.4 Homoeostasis in the skin
Stem cells located in the stratum basale, or ‘mitotic layer’, are responsible for
epidermal homoeostasis. Normal cell replication occurs at a rate which balances
desquamation (skin shedding) at the surface of the stratum corneum and so a
relatively constant thickness of epidermis is maintained. Differentiation occurs as
a reaction to external chemical cues [66, 67] causing cells to undergo mitosis; a
parent cell divides into two daughter cells. In adult humans, one cell stays in the
basal layer and the second moves into the cell layer above. In embryos and infants,
however, the skin is not yet in homoeostasis and cells move sideways to account
for growth [66, 68].
The structure of the epidermis is generally thought to be divided into columns or
‘epidermal proliferating units’ (EPUs) [68, 69, 70, 71]. Here 1 stem cell in 10 in the
basal layer is responsible for cell renewal within that column [72]. This structure
is, however, largely based on research in mouse epidermis. The EPU model has
more recently been disputed by Doupe and Jones [73] who propose an alternative
structure termed the ‘committed progenitor’ (CP) model; which is a probabilistic
model where “the outcome of progenitor cell division is random, with a chance
of generating either two progenitor cells, two differentiating cells or one cell of
each type” [73]. The CP model does not rely on a predetermined fate of cells as
described for an EPU model. A comparison between the two theories presented
by Doupe and Jones [73], finds that the CP model is consistent with historical and
recent data for human skin but conclude that more evidence and improved assay
techniques are needed to resolve this. Considering either of these models on the
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membrane scale, we see the characteristic behaviours of cell turnover observed in
vivo with the whole SC renewing after about 14 days.
3.2.5 Models of skin homoeostasis in the literature
Models of transdermal drug delivery and percutaneous absorption don’t always
include cell turnover in the SC, as often the time scale under consideration is
too short. We expect SC turnover to play a significant role in the formation of
the reservoir and therefore review some models of skin renewal described in the
literature. These models are usually focussed on growth and repair, and consider
the skin on a cellular level. Therefore stochastic models have been used to describe
the skin renewal process from cell division to cell migration [74, 75, 76, 77].
The model presented by Loeﬄer et al.[75] is typical of the type of stochastic
model used to describe epidermal homoeostasis and focuses on cell proliferation
in the basal layer. A two dimensional 32 × 32 matrix of hexagonal cells is set
up representing a top down view of the basal layer. The possibility of EPUs is
discussed and accounted for by dividing the matrix into subunits of 10 cells with
at least one stem cell positioned in each. Stem cells are assumed to be anchored
but lateral displacement by daughter cells is allowed, as well as upward migration.
Five stages of cell development exist in this model: stem cell, three progressive
transit cells and a post mitotic cell. The algorithm starts with the whole cell
layer being scanned for mitotic cells. A selected mitotic cell then divides according
to the value of its ‘cell cycle index’ (assigned to each cell at creation as ‘time
until division’ and adjusted at each time step). Cell displacement is executed
according to the age of neighbouring cells. A dividing cell selects the oldest of
the six immediate neighbouring cells which is then displaced (removed from the
layer). If the selected cell is the oldest cell this cell migrates out of the layer. When
the model is established, a cell labelling scenario is applied in which allocation of
labelling ‘grains’ to daughter cells upon cell division were varied to determine the
most realistic scenario. This kind of cell labelling could be adapted to describe the
presence of a drug in order to apply the model to a scenario of reservoir formation
to consider the movement of a drug within the skin. The disadvantage of this
model type, for our purpose, is that once a cell leaves the layer it can no longer be
detected and is lost from the analysis. It also only considers cell movement and not
the lipid bilayer between cells. Though exact pathways through the SC and binding
mechanisms aren’t known, it is suspected that lipophilic drugs move through the
lipid bilayers around the cells. This cell movement model may therefore be more
appropriate for a scenario where drug binds to, or partitions into, aqueous cells.
Nakaoka et al. describe a model for division and differentiation of stem cells
as a response to chemical cues [76]. A system of delay differential equations is
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established in which cells respond to a ‘growth factor’ (also modelled by differential
equation). The model formulation potentially has more scope to be utilised in a
drug reservoir formation scenario as diffusion through cells is already an established
mechanism, and more skin cell layers are modelled. Again, however, only cells are
considered and there is no immediate way of including movement via lipid bilayers.
Although these models may be of use in the future for drug reservoir formation in
the skin, we believe that their approach is too detailed for our current needs.
3.3 Pathways
In the case of passive transdermal delivery and chemical exposure, the SC has been
identified as the rate limiting barrier. As such, considerable effort has gone into
determining the route of particles traversing this membrane. Three possible routes
have been identified; transcellular (through corneocytes and lipid); intercellular
(through lipid domains only); or via appendages (shunt routes) [52].
The transcellular route refers to the direct route through the SC, partitioning in
and out of cells. It is thought, however, that the cells of the SC may be impermeable
especially for large, lipophilic molecules [78].
The intercellular route refers to diffusion in the intercellular space between the
cells, i.e. through the lipid matrix. This is thought to be the dominant route
through the SC especially for lipophilic drugs [62, 79, 80, 81].
The shunt route could be thought of as the most direct route, bypassing the
SC entirely. These aqueous pathways are thought to be a potential route for
hydrophilic drugs but as appendages only occupy a small area fraction, this route
is generally dismissed in the case of passive delivery [79].
3.4 Review of reservoir formation and passive trans-
dermal delivery models
The only current instance of a mathematical model describing the formation of a
reservoir in the SC caused by the systemic presence of a drug is that of Paulley
et al. [24]. This model for the formation of a lithium reservoir using a non-
spatial compartmental transfer model. The SC compartment is joined to a serum
compartment, and drug enters and leaves the SC compartment via a constant
rate term, representing the turnover of cells. Diffusion of lithium in the SC is
not considered. The model, which comprises a pair of coupled ODEs, is in good
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agreement with available data for both serum levels and extracted fluxes by reverse
iontophoresis (relating to reservoir size calculations). However, as explained earlier,
this is in many ways the simplest case scenario.
In percutaneous absorption models and experiments, we are considering a scenario
where a substance placed on the skin surface enters the body through the skin
via passive diffusion only. In practice this is usually a cream or patch of known
concentration applied to a fixed area of skin in vivo or patch of excised skin in
vitro.
The simplest approach to SC penetration is to assume an idealised, homogeneous
SC [82]. The change in concentration of a drug at a depth x in the SC is then







with the diffusion coefficient in the SC, Dsc, a constant. The steady state flux, Jss,
through the SC is given by the amount of solute, Qss, passing across a surface area,
A, of the skin over a time period T , which is proportional to the concentration
gradient across the SC, ∆Csc, and the diffusion coefficient, Dsc, and inversely








which represents Fick’s first law of diffusion. If we make the further assumption
that the concentration on each boundary is fixed, with sink conditions on one side





These equations are used as a starting point for many models [83, 84, 85, 54, 86,
87, 88]. Complexities such as heterogeneous skin structure, dynamics in vehicle,
binding, more skin layer compartments and other features are subsequently added.
3.4.1 Models of passive transdermal delivery through heterogen-
eous SC
As described in Subsection 3.2.3.4, the SC isn’t a homogeneous membrane, and
actually has a bricks and mortar like structure. Many authors have devised
techniques to incorporate the structure of the SC into their passive delivery models.
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One way to incorporate the heterogeneous nature of the SC is to introduce an
‘effective diffusion coefficient’ or increased path length to reflect the tortuous route
through the SC.
Heisig et al. [89] and Frasche and Barbero [90] use a 2D bricks and mortar structure
of the SC, taking a fixed value for concentration at the skin surface, and sink
conditions at the base of the SC, and using PDEs to describe diffusion through
the SC. Heisig et al. consider a drug that is able to diffuse through both lipids
and corneocytes with a reduced diffusion coefficient through corneocytes, whereas
Frasch and Barbero restrict the movement to lipids only. Heisig et al. demonstrate
the dependence of results on inclusion of permeable corneocytes and the diffusion
coefficients in them. Both models allow for different displacement ratios of the
‘bricks’ between layers and analysis highlights the importance of SC geometry for
predicted time to cross the SC.
Mollee and Bracken [64] consider an alternative method to model passive diffusion
of a lipophilic drug through the lipid bilayers of a bricks and mortar structure. The
pathway of particles is modelled by a one-dimensional PDE using a ‘trapping and
release’ methodology. The x-direction is taken to be transverse to the surface
of the skin. Drug travels between cells from the surface of the skin until it
reaches an obstructing cell, where it remains trapped for the duration of lateral
movement and then continues in the x-direction until arriving at the next cell
(corneocyte). Parameters in their model allow for different alignment of bricks
and mortar and both square and hexagonal cell profiles are considered. Their work
supports previous research demonstrating the impact of considering SC structure
on parameter estimation [61, 63, 89, 90].
3.4.2 Models of passive transdermal delivery that include cell
turnover in the SC
In transdermal delivery, epidermal turnover opposes the absorption of drugs
through the SC.
Cell turnover in the SC was included in the model by Reddy et al. [13], who
also included the turnover of the viable epidermis (VE) and therefore partitioning
between the SC and VE, as determined by chemical properties of the drug. The
focus of this paper was to link the turnover of SC to loss of chemical from the
surface layer. They concluded that epidermal turnover may significantly reduce
systemic absorption for highly lipophilic or high molecular weight (MW) chemicals,
but is not expected to have a huge impact on most other chemicals.
Motivated by the reservoir effect of the SC for corticosteroids, Roberts et al.
investigated the impact of desquamation on this reservoir [8]. The paper uses a well
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mixed compartment to represent the SC connected to a VE compartment, which is
in turn linked with a systemic circulation compartment. Diffusion wasn’t directly
considered, but was accounted for by a first order rate term for movement of drug
from the SC compartment to the VE compartment. Desquamation was accounted
for by a constant removal rate from the SC compartment. The authors conclude
that desquamation will only affect the reservoir formation when the penetration
rate of the solute is comparatively slow. The effect of desquamation is therefore
also more pronounced for diseased skin, where turnover is increased.
In 2011, Simon et al. included the effects of epidermal turnover in their
mathematical drug delivery model to explore the influence of turnover on the
time taken to reach steady state delivery [85]. A single species of drug in the
SC and viable epidermis is considered, using a pair of coupled one-dimensional
PDEs, diffusion and desquamation are modelled in both skin layers using diffusion-
advection equations. The model is solved using Laplace transforms and the residue
theorem to provide an analytical solution. They conclude that lipophilicity and
high MW hamper transport due to a low diffusion coefficient, supporting the
findings of Reddy et al. [13] and Roberts et al. [8].
3.4.3 Models of passive transdermal delivery that include binding
Binding of drug in the SC has been considered in a number of cases [12, 91, 92, 93].
As only unbound drug is free to diffuse, binding of a drug in the SC may impact
the rate at which a drug crosses the SC.
Nitsche and Frasch explore the consequences of linear reversible binding on dermal
absorption [12]. A coupled system of equations is used representing bound and
unbound drug in the skin with linear transfer between the two and only unbound
drug free to diffuse. In this paper they consider the SC on a cellular level with
a bricks and mortar like structure. The goal is to approximate the behaviour
observed here on a membrane scale, and to estimate effective coefficients for this
analogous membrane scale model. They find that, when considering transcellular
transport, forward and reverse binding rate constants for each microscopic phase
(lipid and corneocyte) must be included. However they acknowledge that data for
these parameters is generally unavailable and call for further experimental work
to determine a relation between these values and properties of a chemical such
as lipophilicity (Koct) and MW. They also conclude that a significant fraction of
transdermal delivery does not occur at steady state but instead at the ‘transient
regime’.
Pontrelli and de Monte also addressed binding dynamics in passive transdermal
delivery [92]. In this model they consider bound and unbound drug in homogeneous
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Figure 3-4: Schematic for Model 2 where SC (x = [0, L]) is the stratum corneum
and VE is the viable epidermis represented by ‘poorly perfused tissues’ from Model
1, Cu, Cb are the unbound and bound drug in the SC and Ru, Rb are the unbound
and bound drug in poorly perfused tissues (from model 1). Dotted arrows denote
diffusion of unbound drug (diffusion coefficient D) and dashed arrows denote
convective movement of bound and unbound drug due to the renewal of the stratum
corneum at rate v.
skin and the delivery vehicle, with reversible binding in both. This is modelled in
one spatial dimension, normal to the skin surface. Initially all drug is bound in the
vehicle, drug unbinds (and binds) at a constant rate, and unbound drug partitions
into skin where it can reversibly bind. At the base of the skin drug is cleared by a
capillary system following first order kinetics. Only unbound drug is free to diffuse
and partition from vehicle into skin. Analysis highlights the importance of the
ratio of binding to unbinding parameter values in both the vehicle and skin, as
these affect the whole drug transfer process. The authors suggest that the analytic
results provide important information for drug selection and experimental design
for optimal drug transport.
3.5 Modelling
In this section we create a mathematical model to describe the formation of a drug
reservoir in the stratum corneum. Our hypothesis is that the systemic presence of
a drug causes a build up in the SC to create a reservoir, where inflow from poorly
perfused tissues is balanced by a loss from the skin surface.
Drug binding in skin In Model 1 (equation 2.19) in Chapter 2, we considered
bound and unbound drug in the plasma and tissues. Drug binds to keratin in the
skin [14] and the dynamics of binding in the skin have been shown to be linear
[91]. As only unbound drug is free to diffuse [12], binding may be an important
factor in the formation of a SC reservoir. We therefore consider both bound and
unbound drug in the SC and allow for the possibility of binding and unbinding.
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Passive diffusion through the skin Movement of unbound drug into the skin
occurs via passive diffusion down a concentration gradient and is described by
Fick’s law of diffusion assuming a constant diffusion coefficient, D > 0.
Movement with the differentiating cells Cells and intercellular material in
the skin move from the viable epidermis to the skin surface where they are shed
[52, 94]. We are considering the movement of drug from the base of the SC to
the skin surface i.e. with the direction of movement of renewing cells. Epidermal
turnover and desquamation is affected by many variables including hydration, time
of day and skin condition. Here we focus on the underlying mechanism and assume
that the skin moves towards the body surface at constant velocity, v > 0.
We consider a one-dimensional spatial domain for the SC since we assume that
the drug is distributed homogeneously across the viable epidermis (VE), the layer
below the SC, and approximate the SC as laterally homogeneous. We take x = 0
to correspond to the boundary between the SC and VE, and x = L to the surface
of the skin.
We let Cu(x, t) and Cb(x, t) denote the concentration of unbound and bound drug
at x, at time t, respectively and develop a diffusion-convection model based on the
schematic shown in Figure 3-4, assuming that
1. unbound drug diffuses across the SC with diffusion coefficient D > 0.
2. bound and unbound drug move towards the surface of the skin at constant
velocity, v > 0, corresponding to the cell renewal in the SC.
3. bound drug becomes unbound at the rate µ > 0, and unbound drug becomes
bound at rate γ > 0.
4. at x = 0, concentrations of bound and unbound drug correspond to those
values obtained from the poorly perfused tissue in the compartmental model,
Rb(t), Ru(t) respectively.
5. at x = L, we assume no diffusion across the surface of the skin of the unbound
drug i.e. at x = L flux is vCu.













− µCb + γCu. (3.1b)
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At x = 0, the interface between the stratum corneum and viable epidermis, the
boundary conditions are
Cu(0, t) =αRu(t), (3.2a)
Cb(0, t) =αRb(t), (3.2b)
where α represents partitioning between poorly perfused tissues and the SC and
where Ru(t) and Rb(t) are outputs from Model 1. Boundary conditions at the






= 0 (no diffusion across skin surface). (3.3)
3.5.1 Calculation of Steady State Drug Distribution in the SC
Assuming a constant dosing regime, we approximate plasma and tissue concentra-
tions by their average values and assume constant boundary conditions
Cu(0, t) = αRu(t) = αR¯u, αRb(t) = α ¯Rb = Cb(o, t),
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The eigenvalues of the system are




































































Hence the steady state distribution in the SC is given by.
C = av0 + bv+ exp(λ+x) + cv− exp(λ−x), (3.10)
where a, b and c are constants, found using boundary conditions (3.2) to be



















λ−[(exp(λ+L)(µ+ λ+v)− exp(λ−L)(µ+ λ−v)] . (3.13)
We use these distributions to explore the form and size of a drug reservoir in the
skin.
Note that if we consider binding and unbinding occurring at an equal rate
(µ = γ) and constant boundary conditions with equal concentrations of bound
and unbound drug (αRu = αRb) then from equations (3.11-3.13) c=0 and so b=0
giving a=αRb. Using this in equation (3.10) the steady state solution of drug in
the SC for equal binding and unbinding rates and equal bound and unbound drug
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i.e. we expect no spatial dependence in the steady state reservoir concentration.
The reservoir size per unit surface area of the skin is then given as
Su = αRuL = Sb. (3.15)
3.5.2 Reservoir Size
We define the size of the reservoir to be the amount of drug across the entire
thickness of the stratum corneum at steady state for a given unit of cross sectional































(exp(λ−L)− 1) , (3.17)
where a, b, and c are constants as defined by equations 3.11-3.13 and λ+and λ−
are given by equations (3.7) and (3.8).
We use these expressions to explore how changes in model parameters affect
reservoir size.
3.5.3 Bricks and mortar structure
To cover the thickness of the SC (a distance, L) solely by diffusion would take
average time τD = L
2/D and by convection would take average time τC = L/v
which means that when D = Lv, the time taken to transit the SC is the same
for both movement mechanisms. The stratum corneum is known to have a bricks
and mortar like structure [54, 61]. For lipophilic drugs we expect the primary
route of diffusion will be via the lipid matrix i.e. intercellularly [62]. To follow
this route, the drug molecules must move around the flat keratinised cells that
are embedded in the matrix [52], which means that their path length through the
SC LD will typically be longer than the domain size L. To account for this in
our one-dimensional model, the model diffusion coefficient D is modified from the















Based on this argument we represent a longer, more tortuous route through the
SC with a lower diffusional coefficient in our one-dimension spatial model.
3.6 Results
In this section we explore the dependence of the reservoir size and time to steady
state on key parameters including binding and unbinding parameters, diffusion
coefficient and drug distribution at the lower SC boundary.
3.6.1 Parameter Values used in Numerics
The thickness of the SC (L) is dependent on many variables including region of
the body, age, gender and health. In a study by Sandby-Moller et al.. [95] the
average thickness of the SC for the forearm, where skin sampling is usually taken,
is given as 18.3µm and it is this value chosen for L in numerical simulations.
The time taken to renew the SC is typically taken to be 14 days for a healthy adult
[96, 97, 94] and we therefore take v to be 0.054µmh−1.
Values of D,µ and γ are drug dependent and are often uncertain or unknown.
Boundary values αRu and αRb come from the first model and are consequently
variable and depend on drug and drug intake. We therefore explore the dependence
of our reservoir size on these unknown parameters.
3.6.2 Dependence of reservoir size on binding
The importance of binding parameters in transdermal drug delivery has been
highlighted recently in a paper by Pontrelli and de Monte [92]. A comparison
between reservoir size and diffusion coefficient, D, for different binding rates with
different bound/unbound ratios at the boundary is given in Figures 3-5 and 3-
6. From this we can see that for sufficiently large D, reservoir size approaches
a constant value dependent on the boundary conditions and binding rates. The
relative proportion of bound to unbound drug in the reservoir at steady state
appears to be controlled by the binding rates, γ and µ, whereas the scale of the
reservoir is affected by a combination of the ratio of bound/unbound drug at the
boundary and the rates of binding, γ, and unbinding, µ, in the SC.
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(a) µ=5, γ=1, αRu = αRb=1
D


















(b) µ=5, γ=1, αRu=0.08 αRb=1.92
Figure 3-5: Steady state reservoir size plotted against D for the cases µ > γ with
(a) even (αRu = αRb = 1) and (b) uneven (αRu = 0.08, αRb = 1.92) binding
on the constant boundary at x = 0. As parameter values chosen here are for
qualitative exploration, units of reservoir size have been omitted.
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(a) µ=1, γ=5, αRu = αRb=1
D



















(b) µ=1, γ=5, αRu=0.08 αRb=1.92
Figure 3-6: Steady state reservoir size plotted against D for the cases µ < γ with
(a) even (αRu = αRb = 1) and (b) uneven (αRu = 0.08, αRb = 1.92) binding
on the constant boundary at x = 0. As parameter values chosen here are for
qualitative exploration, units of reservoir size have been omitted.
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Next we explore how the reservoir size depends on the binding and unbinding rates
whilst keeping D fixed, and boundary conditions constant. In Figure 3-7(a) we
vary γ and observe that the total reservoir size increases essentially linearly with γ,
driven by an increase in the amount of bound drug. Variation in γ has no effect on
the amount of unbound drug in the reservoir at steady state (due to the non-zero
value of D).
In Figure 3-7(b), we vary µ (unbinding) and in this case observe that the total
reservoir size is inversely proportional to µ, again driven by a similar relation
between bound drug and µ. From both graphs we see that binding mechanisms
of drug within the SC may prove a crucial factor in expected reservoir size.
Moreover the comparative levels of bound and unbound drug may be significant
when considering extraction of the reservoir. If, for example, only unbound drug
is retrieved with a given extraction method, high binding and low unbinding may
decrease rather than increase observed reservoir size.
3.6.3 Dependence of reservoir size on boundary drug distribution
In Figure 3-8 we show how the binding ratio for drug in the poorly perfused tissue
(Figure 2-11) impacts on reservoir size. From this figure we note that; in all cases,
as the percentage of drug that is unbound increases in the body, the reservoir size
increases, and when the rate of binding exceeds the rate of unbinding in the SC,
the reservoir size is significantly larger than when this relation is reversed. Again
this has relevance for the extraction process as detailed above in Subsection 3.6.2.
3.6.4 Time to form reservoir
Whilst steady state reservoir size provides valuable information about the scale of
the drug storage in the skin, it does not provide any information on how long it
takes for the reservoir to form. This is an important measure as it indicates how
sensitive the reservoir size is to a change in the boundary condition and therefore
how quickly it will reflect a change in dose.
In the case where the rate of unbinding is greater than the rate of binding (µ > γ),
illustrated by Figures 3-9(a) and 3-9(b), the time taken to reach steady state
decreases with an increase in D, i.e. the faster the diffusion of unbound drug, the
quicker the reservoir is able to settle to its steady state level. For small D the
accumulation of the reservoir is initially slower than for large D but over time this
reverses. This is because initially, greater diffusion allows unbound drug to access
the whole region before becoming bound and so the reservoir builds rapidly but
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(a) D = 0.5, µ=1, αRu = αRb=1
µ




















(b) D = 0.5, γ=1, αRu = αRb=1
Figure 3-7: Steady state reservoir size plotted against (a) binding rate, γ with
constant µ = 1 and (b) unbinding rate µ, with constant γ = 1 both graphs plotted
using constant diffusion, D = 0.5 and constant boundary conditions at x = 0,
αRu = αRb = 1. As parameter values chosen are for qualitative exploration, units
of reservoir size have been omitted.
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% Drug Unbound on Boundary at x = 0



















(a) µ = 1, γ = 5, D = 1
% Drug Unbound on Boundary at x = 0


















(b) µ = 1, γ = 1, D = 1
% Drug Unbound on Boundary at x = 0


















(c) µ = 5, γ = 1, D = 1
Figure 3-8: Steady state reservoir size plotted against percentage of drug unbound
on boundary x = 0 for constant total boundary condition αRu + αRb=2 for (a)
µ > γ (b) µ = γ (c) µ < γ. As parameter values chosen are for qualitative
exploration, units of reservoir size have been omitted.
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Time hours


































(a) µ = 2, γ = 1
Time hours
































(b) µ = 2, γ = 1
Time hours































(c) µ = 1, γ = 2
Time hours





























(d) µ = 1, γ = 2
Figure 3-9: Reservoir size plotted against time for diffusion coefficient D = 0.05,
0.5, 1 and 2 with constant boundary conditions, αR¯u = αR¯b = 1 for unbinding
rate µ and binding rate γ a) unbound drug with µ > γ, b) bound drug with µ>
γ, c)unbound drug with µ < γ, d) bound drug with µ < γ. As parameter values
chosen are for qualitative exploration, units of reservoir size have been omitted.
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as the unbound drug spreads through the region, having smaller diffusion allows
more drug to become bound and hence the reservoir size increases.
In the case where the rate of binding is greater than the rate of unbinding (γ > µ),
Figures 3-9(c), 3-9(d), the time taken to reach steady state increases with an
increase in D. This is because in this case at steady state we expect more bound
than unbound drug in the reservoir. The dominant equation in this case is therefore
equation (3.1b). When D is sufficiently small, the governing equation for unbound
drug (equation (3.1a)) is in agreement with the bound equation and both bound
and unbound drug move through the domain with the skin (v), allowing for local
binding dynamics to settle quickly and therefore reaching steady state quickly.
However presence of diffusion in equation (3.1a) disrupts the system, with larger
D values causing a greater perturbation and therefore taking longer to reach steady
state.
In Figure 3-10(a) we show how quickly a perturbation to the drug concentrations
at the boundary affects the reservoir size, depending on the diffusion coefficient.
To explore this behaviour µ, γ are set to 1 so that the effect of differing binding
rates does not influence our results and similarly we take ¯αRu = ¯αRb = 1 so that
drug concentrations at the boundary x = 0 are equal. In this figure, at t = 500h a
perturbation is applied at the boundary for 24 hours, we see that for larger values
of D, the effect of the perturbation is more pronounced than for small D values
but that the time taken to return to a steady reservoir size is much less for large
diffusion coefficients than small diffusion coefficients.
This will be of importance when considering a fluctuating boundary condition as
we have in the body. A larger D would result in a shorter time to steady state (i.e.
equilibrating with in body concentrations quickly) which means that the reservoir
size would reflect changes in body concentration more dramatically; meaning traces
of a fluctuation will also be removed more quickly. Whereas a smaller D would
result in a reservoir that is less sensitive to in-body concentration fluctuations.
Note that choices of γ and µ in the above figures are arbitrary. Figures shown
are representative of the cases where µ > γ and γ > µ and similar profiles were
obtained for other choices of these unknown parameters.
3.7 Conclusion
Using information available in the literature, the SC was identified as the most
likely location for a reservoir to form in the skin. A model to describe the formation
of a reservoir in the SC was then created which includes both bound and unbound
drug with linear reversible binding, diffusion of unbound drug, and cell renewal in
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Figure 3-10: (a) Total reservoir size plotted against time for diffusion coefficient
D = 0.05, 0.5, 1 and 2 with constant boundary conditions, αR¯u = αR¯b = 1 and
equal binding and unbinding, µ = γ = 1. with a perturbation to the boundary
conditions at t = 500h for 24 hours of αR¯u = αR¯b = 2. (b) Enlarged view of
Figure 3-10(a). As parameter values chosen are for qualitative exploration, units
of reservoir size have been omitted.
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the form of a linear advection term which moves both bound and unbound drug
to the skin surface. The bricks and mortar structure of the SC was also accounted
for by use of an effective diffusion coefficient.
The importance of binding in transdermal delivery has been shown previously
[12, 92]. Our model demonstrates that binding may also be an important factor in
the formation of a reservoir from systemic presence affecting both reservoir scale
and time to reach steady state.
One of the key movement mechanisms included in our model is SC turnover
and desquamation. Though SC turnover isn’t always considered in drug delivery
models it is the only mechanism of drug movement through the SC included in the
model by Paulley et al. [24], and as the main method of removal of drug from the
SC it provides the rate limiting factor for storing of drug information in skin.
Analysis has also provided insight into the time scales associated with reservoir
formation and response to in-body changes in drug concentration. Moreover, the
system lends itself well to the exploration of non-invasive extraction and drug
monitoring techniques across the skin as it describes both total amount in the SC
and also spatial distribution of drug in the SC. The first measure is relevant to
extraction techniques such as reverse iontophoresis whilst the second lends itself to
the process of tape stripping. This model was created to take values from Model 1
in Chapter 2 and provide a description for resulting reservoir size. This model will
be used to give IC for the extraction model developed in Chapter 4. In Chapter 5
the combination of these three models will be explored.
This work was conducted with a lipophilic drug in mind and so only the
intercellular pathway was considered. In the future this model could be expanded
to consider other routes through the SC. The transcellular pathway could be
incorporated using a trapping and release method as used by Mollee and Bracken
for an intercellular approximation [64]. This method could be adapted with
the use of a partitioning term in and out of cells for the transcellular route.
In the introduction to this chapter various models of skin homeostasis were
discussed. It is not currently fully understood where the drug in the SC resides
as techniques involve breaking down the SC structure when sampling. However if
this information becomes available in the future, stochastic cell based models may





In this chapter we focus on the third of our three models as shown in Figure 4-
1. When a drug reservoir has become established in the SC we want to detect
its presence and, if possible, determine something about the magnitude of the
reservoir. We consider reverse iontophoresis as a mechanism for extracting drug
that has accumulated in the SC.
We begin by describing the process of (reverse) iontophoresis and the necessary
mathematical background. We go on to review models of (reverse) iontophoresis
in the literature and use ideas here to create a model for reservoir extraction via
reverse iontophoresis. We then examine the impact of assumptions made in the
modelling process.
4.2 Reverse Iontophoresis
Iontophoresis is a transdermal drug delivery technique. Two cells are placed on
the skin surface, one attached to an anode, the other to a cathode, as shown in
Figure 4-2. The drug for delivery is placed in the ‘donor’ cell which is determined
by the properties of the drug being delivered. A current is passed between the two
cells which causes an ion flow; positive ions move towards the cathode and away
from the anode and negative ions move in the opposite direction. This encourages
movement of the drug from the donor cell into the body.
Reverse iontophoresis is a relatively new technique for non-invasive drug monitor-
ing. It works on the same principles as iontophoresis but initially there is no drug
in either cell. Empty cells, or ‘collection pads’ attached to electrodes are placed
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Figure 4-1: The overall aim is to create three composite models which will be
linked together to create a model which predicts the expected reverse iontophoresis
reading for a given drug administration regimen and therefore interpret reverse
iontophoresis readings in the context of historical (order of days/weeks) drug
monitoring. The third model, for the extraction of a drug reservoir in the skin, is
the focus of this chapter.
on the skin surface and again a current is passed between them causing positive
and negative ions to move towards the opposing electrode and accumulate on the
collection pads there.
Transdermal iontophoretic drug delivery is a much more widely used and well
established technique than reverse iontophoresis and as such there is much more
literature on iontophoretic delivery. However, the principles and mechanisms of
movement involved are similar, and so much of the literature for iontophoretic
delivery is relevant for reverse iontophoretic extraction modelling.
There are some key differences between iontophoresis and reverse iontophoresis
that need to be considered when creating the model. In iontophoretic drug delivery,
the source of the drug being considered is the donor cell on the skin surface; in
reverse iontophoresis the source of the drug comes from within the body. An in-
body concentration would usually refer to systemic concentration as determined
by blood plasma concentration but in our case we also consider drug initially
in the SC, which is in the path between the collection pads and the plasma.
In transdermal delivery studies, drug administered is therefore at comparatively
large concentrations, whereas during extraction the concentration in the blood
will, generally speaking, not be significantly greater than the therapeutic blood
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Figure 4-2: Diagram of iontophoretic set up with photo of apparatus taken from
Tesselaar and Sjo¨berg [98].
concentration; moreover, concentrations of drug present in the stratum corneum
reservoir are expected to be smaller still.
During delivery it is often assumed that the continual clearance of drug from
lower (viable) skin levels by the blood provides constant sink conditions at the
boundary. During extraction collection pads are replaced at regular intervals in
order to maintain sink conditions at the boundary.
In both cases the movement of particles can be described by three key processes;
electromigration, electroosmosis, and increased passive diffusion, as described in
the following sections.
4.2.1 In vitro experimental set up
The process of (reverse) iontophoresis is mimicked in vitro by placing a sample of
skin (SC or SC+VE) between two cells, one filled with a ‘donor’ solution and the
other with a ‘receptor’ solution. An anode is placed in one cell and a cathode in
the other (determined by the drug being delivered). The donor solution contains
the drug for delivery and often also contains a buffer to maintain a constant pH.
The receptor solution also contains a buffer, usually to replicate physiological pH.
Depending on the experiment the receptor solution may be continually replaced
to maintain sink conditions.
Plasma has a lower resistivity than lower layers of the epidermis and so we expect
the lateral current flow in Figure 4-2 to be through the plasma (see Figure 4-3).
As the comparative resistivity of the SC is so high, no lateral movement of current
is expected in this layer. For this reason, as we are usually only interested in
movement of drug in one direction, the in vivo set up (electrodes on the same side
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of the skin) can be approximated by the in vitro set up (electrodes on opposite





Figure 4-3: Simple circuit diagram of 2 resistors in parallel to explain why we
expect no lateral movement through the SC. Provided the separation between
the collection pads is sufficiently large, the resistance of the path through the
SC (represented by R1 here) is much greater than the resistance of the path
through the plasma (R2) and we expect the current reading at A2  A1 i.e the
current travels almost completely through the plasma. It is for this reason we don’t
consider lateral movement through the SC and only consider movement through
the plasma (and not lower levels of the epidermis).
4.2.2 Pathways
The exact pathway of permeants through the SC during iontophoresis is not
known for sure. It is currently thought that the most likely route through the
SC during iontophoresis is via the appendages (shunt route). Appendages in
humans include hair follicles, sweat ducts and sebaceous glands. It is thought
that during iontophoresis these aqueous routes are dominant as they offer a low
resistance pathway [99]. However the appendages listed do not account for the
number of pathways observed [100]. A porous skin model has been suggested which
includes these appendages with other pores made up of localised skin imperfections
where porous pathways ‘open up’ on the application of an electric field [100].
Evidence presented by Bath et al. [101] suggests that bulk flow, as described by
electroosmosis, is exclusively through aqueous pores.
The intercellular route is the tortuous route via the lipid domain, suggested as the
route of passive diffusion of lipophilic substances. As electrical current takes the
path of least resistance, movement due to electrostatic repulsion (electromigration)
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and bulk fluid flow (electroosmosis) is unlikely to be through the lipid domain
as lipids are poor conductors. It has, however, been hypothesised that due to
an increase in temperature caused by the current flow, fluidity of lipid bilayers is
increased leading to enhanced passive diffusion in this domain during iontophoresis.
Hydration of the skin can cause pores to swell and close, suggesting hydration
of the SC may significantly impact movement via this route. It has been shown
that iontophoresis can directly affect the hydration levels, particularly in in vitro
experiments where skin samples have been (partially) dehydrated or frozen prior
to use.
4.2.3 Electromigration
Electromigration describes the movement due to direct electrostatic repulsion of
ions from an electrode of the same charge. This transport is only relevant for ionic
(charged) particles and is more prominent for small, mobile (unbound) ions [19].
Electromigration has been identified as the key movement mechanism for charged
species [101].
Electrical current is defined as the flow of charged particles through a conducting
material. It therefore follows that the flux of any given ion is proportional to the





where F is Faraday’s constant, I is the current, zi is the valency of ion i, and ti is
the transport number. The transport number of a given ion is the proportion of
total charge carried by that ion, Ii = tiI and is given by
ti =
Ciziµi∑
j Cj |zj |µj
, (4.2)
with µi, the ion mobility and Ci the concentration of the ion. The transport
number of an ion is dependent on all ions present.
Faraday’s law of electrolysis, equation (4.1), has been used to describe elec-
tromigratory flux in transdermal iontophoresis in a number of publications
[19, 102, 103]. More commonly, however, electromigratory flux of an ion, i, is







where Di is the diffusion coefficient of the ion, zi is the valency of the ion, Ci is the
concentration of ions, kT is the thermal energy of the system, e is the charge of
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an electron and E is the magnitude of the electric field. The first term in equation
(4.3) relates to passive diffusion, and the second term to electromigration.
Equivalence between the electromigratory term in the Nernst-Planck equation (4.3)
and Faraday’s law (4.1) is shown below.
First we consider an ion, i, in a viscous fluid (the SC) with imposed electric field
E. The force on the particle due to the field is given by
Fi = zieE, (4.4)
where zie gives the charge on the particle. This force is balanced by the drag on
the particle given by Stokes’ law for drag on a small spherical object in a viscous
fluid. This can be derived by solving Stokes’ flow limit for small Reynolds number
in the Navier-Stokes equations, which gives
Fi = 6piηrivi (4.5)
where η is the viscosity of the SC, ri is the radius of the particle and vi is the
flow velocity relative to the object (drift velocity). Equating (4.4) and (4.5) and





Drift velocity for an ion in electric field E is also given by Ohm’s law as
vi = µiE. (4.7)

















Now, if we consider the electromigratory component of flux as given in the Nernst-
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using equation (4.10) we can rewrite equation (4.11) to give
Ji = µiECi. (4.12)
Again, using Ohm’s law (as reformulated by Kirchhoff),
Ii = σiE (4.13)











The approach of Nernst Planck usually coincides with a fixed electric field, which
means that, as the resistivity of the SC changes during iontophoresis the flux of
ions will change too. A fixed current however, corresponds to a fixed flux of ions,
with the relative flux of each ion determined by properties of all of the ions present.
Moreover, as the (change in) resistance of the SC is subject to significant inter and
intra patient variability a fixed current may significantly reduce this variability
[102, 104, 105, 106].
It is for this reason that many studies choose a fixed current over a fixed electric
field in experimental work.
As stated previously, the concentration of drug considered in transdermal delivery
is orders of magnitude greater than the concentrations of drug expected in an
extraction scenario. Therefore competition for charge with other ions present
is usually ignored in delivery studies. In transdermal extraction more than one
ion is present in the SC and we expect that the ion of interest will not be the
most abundant; effects of ion competition may therefore become more significant.
We therefore choose to maintain a constant current and include ion competition
through the use of Faraday’s law to model electromigratory flux.
4.2.4 Electroosmosis
Uncharged species have no direct interaction with an applied electric field.
However, it has been shown that iontophoresis enhances the delivery of neutral
species [105, 106, 107]. The cause of this increased transport is thought to be
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electroosmosis [108]. Electroosmosis has been identified as the key movement
mechanism for iontophoretic delivery of neutral substances [101] and large cations
(>1000 Dalton)[109].
Electroosmotic flow is bulk solvent flow under an electric field. It occurs in
membranes with a net charge, and the direction of flow is always in the direction
of counter ion flow [110, 111, 112]. Electroosmotic flow can therefore be with or
against the current flow. As skin is negatively charged above pH 4, flow is from
anode to cathode [108]. Electroosmosis in the skin therefore reinforces movement
due to electromigration for cations whilst acting against electromigration of anions.
As mentioned previously, electrical current takes the path of least resistance and
so it is generally accepted that electroosmosis will occur solely in the aqueous
domain [101, 113, 114]. Assuming a porous skin model, we therefore consider
electroosmosis occurring exclusively in pores or channels.
For uncharged particles and particles with Stoke’s radius > 1nm this is the
dominant flow mechanism. Moreover, both theory and experimental data indicate
that electroosmotic flow increases in importance as the size of the ion increases
[108]. This is because, although electroosmosis itself is independent of molecular
size [113, 110, 115] (provided it doesn’t approach the size of the pathway [111, 116]),
as size increases, relative contributions of passive and electromigratory flux
decrease [109].
When temperature, pressure, and fluid composition on both sides of the membrane
are equal, electroosmotic volume flow is directly proportional to the potential
gradient [117]. Flux due to electroosmosis can therefore be written





where Jv is the volume flow, LV E is the electroosmotic flow coefficient, and
−dφ
dx
is the potential gradient.
The flux due to electroosmosis, Jv, can be described in terms of the velocity of the
flow, vf , as
Jv = vfA (4.17)
where A is the area considered for the flux, and vf for zero pressure gradient is
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where  is the permittivity, η is the absolute viscosity and ζ is the zeta potential.





where ρ is the resistivity.
However, as the values for concentration, mobility etc. are for within the SC,
estimation is difficult and values are subject to significant inter-patient and intra-
patient variability. We therefore follow the lead of many transdermal delivery
models [101, 119, 120] and use the simplification
Ji = JvCi, (4.20)
where
Jv = veoI
and we take veo to be a constant value over the area of interest (beneath the
collection pad). Experimental work by Pikal and Shah [121] gives
veo = (6− 19)µlh−1mA−1. (4.21)
4.2.5 Enhanced Passive Diffusion
It has been shown in many studies that, provided the safe limit of 0.5mAcm−2
[122, 123] is not exceeded, there is no long lasting damage to the skin i.e. passive
permeability coefficients post-iontophoresis return to their original values [120,
124]. However there is some evidence to suggest that during iontophoresis there
is a drop in resistivity of the SC which also causes the passive flow of ions and
neutral species to increase during this time [121, 122, 123, 125].
It is thought that the cause of this reduction in resistivity may be the ‘opening of







A decrease in resistance relates to increased mobility of ions, µi. On inspection
of the diffusion coefficient, Di =
kTµi
zie
, we see that an increase in mobility µi,
would also increase the diffusion coefficient, therefore increasing the contribution
of passive diffusion. However, the impact of an increase in passive diffusion is
not expected to be large as the contribution of passive diffusion compared to
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electromigration (EM) and electroosmosis (EO) is still small. The effect becomes
more noticeable when the reverse iontophoresis is stopped and passive diffusion is
still temporarily increased. This concept is explored by Nugroho et al. [126, 127],
described in detail in the literature review Section 4.3.
4.2.6 Skin pH and Ionisation
The ionisation of a substance depends on the pH of the environment that it is in.
The pH of the stratum corneum varies depending on the depth within the SC, with
the surface pH estimated to be 4.5 for men (and 5.3 in women) increasing to a pH
of 6.8 (6.9) in the stratum granulosum at the base of the SC [128]. pH variation in
the SC is dependent on a number of factors such as race [129, 130], age [131, 132],
gender [128, 131] and even time of day [133].
As only ionised drug will move via electromigration [19] it is important to have
an idea of the proportion of drug that is ionised in the skin. Again we use
buprenorphine as the exemplar drug by which we make modelling decisions. The
pH at which the substance is exactly half dissociated (ionised) is known as the
pKa and for buprenorphine pKa = 8.31. Buprenorphine is a base, meaning that
we expect buprenorphine ions to have a positive charge; a buprenorphine ion has
valency +1. To determine the proportion ionised in the skin we use the Henderson
Hasselbalch equation for bases,






where [B] denotes concentration of neutral substance and [BH+] denotes concen-
tration of (positive) ions. For simplicity we consider skin to have pH within the
range pH4-6 [132], using this with the pKa for buprenorphine in (4.23) we expect
buprenorphine to be 99.9%-99.5% ionised in the SC. Therefore for the possible
range of pH values in the SC, bup is essentially completely ionised. Moreover,
considering physiological pH 7.3, we would expect bup to be 91.1% ionised in the
plasma and so we expect that change in pH and therefore change in ionisation will
not have a significant impact on the predicted or observed transport.
For drugs with a lower pKa, especially drugs with pKa close to skin pH, changing
ionisation may be an important factor for extraction.
4.3 Literature Review
There is very little in the literature specific to reverse iontophoresis and even
less in the way of mathematical models. In fact the only mathematical model
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of reverse iontophoresis known is the 2010 paper by Paulley et al. [24]. In this
paper the authors consider a chronic administration of lithium where the drug
has built up to form a reservoir in the SC over time. It is assumed iontophoretic
extraction of lithium, a small positively charged ion, is by electromigration only. It
is modelled using a system of ODEs with movement via electromigration based on
Faraday’s law of electrolysis, using transport numbers as described in Section 4.2.3.
A constant current is assumed. Lithium is extracted via reverse iontophoresis from
well mixed SC and mixed plasma compartment through independent routes. The
results show an initially high extraction which levels off as the reservoir is emptied,
with subsequent extraction from plasma only, which is in agreement with available
data. However, during reverse iontophoresis for a drug-naive patient, a lag time
(lower initial extraction) is expected due to the time taken to cross the skin. In this
paper the extraction from plasma is independent of extraction from the SC and is
modelled using non-spatial compartments. Therefore the expected lag time is not
replicated by this model (not shown in paper). This lag time from plasma would
still be present in a chronically dosed patient but the initial low reading is masked
by the high reading for the reservoir extraction. This means that, for a given
reservoir size, initial readings would be over predicted by this model, potentially
causing reservoir sizes to be underestimated. The results in this paper, however,
show good qualitative agreement with data for chronically dosed patients and the
model provides a starting point for modelling of reservoir extraction via reverse
iontophoresis.
The most simple models for iontophoretic delivery describe the in vitro experi-
mental set up with a homogeneous membrane and usually focus on one, two or all
three of the transport mechanisms (electromigration, electroosmosis and diffusion)
as determined by the drug of interest. Some papers have attempted to make models
more realistic by addressing the membrane structure, pathway of the drug or by
including more drug specific characteristics.
Keister and Kasting consider iontophoretic delivery under a uniform electric
field [125]. They consider movement of an ionised drug across an uncharged
homogeneous membrane (i.e. no electroosmosis) with infinite sink conditions on
the acceptor side of the membrane. They therefore model the movement through
the membrane using the Nernst-Planck equation (electromigration and diffusion)
as described in Section 4.2.3. They quantify the effects of iontophoresis by an
‘enhancement ratio’ i.e. ratio of steady state flux under applied voltage to steady
state passive flux, and ratio of iontophoretic lag time to passive lag time. They
conclude that the application of an electric field leads to an enhancement in drug
delivery proportional to the magnitude of the electric field applied.
Bath et al. consider constant current iontophoresis of an anion, cation and neutral
molecule through hair follicles in hairless mouse skin, to determine the relative
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contribution of electromigration, electroosmosis and diffusion in each case [101].
Their work is mainly empirical. In their model, movement via electromigration
is expressed using the Nernst-Planck equation, with electroosmosis described by a
simple linear convection term. In this paper they consider the impact of changes in
skin pH on the electroosmosis term. To avoid dealing with a change in diffusion due
to a change in resistance of the skin, the work considers steady state transport. In
order to do this experimentally, a constant current is applied across the skin sample
until a steady state skin resistance is reached before taking any measurements.
Their findings show electroosmotic flow velocity is independent of the charge of the
permeant, which is supported by findings of Guy et al. [109]. They also find that
electroosmotic flow velocity is directly proportional to the applied current. They
conclude that a significant fraction of iontophoretic transport for all permeants
occurs through hair follicles.
Roberts et al. consider iontophoretic delivery of partially ionised drugs of a range
of radii through a porous model of the SC [116]. Movement mechanisms through
aqueous pores considered are electromigration, electroosmosis and diffusion.
Simultaneous passive diffusion via lipids is also considered with the pathways
independent of each other. Pores only occupy a certain area fraction of the SC and
it is predicted that solutes with radius approaching the size of pore radius may be
more impeded than small molecules. Two separate approaches are considered to
model the porous structure of the SC, based on the papers by Yoshida and Roberts
[134, 135]; a free volume model in which there is limited space where molecules
can enter to transport through pores; and a pore restriction model where there
is steric hindrance on entry into the pore and movement within the pore due to
friction with the pore wall. Both forms of the model were found to be consistent
with experimental data, with the pore-restriction model outperforming the free
volume model for prediction of solute size effects on iontophoresis.
Imanidis and Luetolf [120] make the distinction between aqueous and lipid domains
in the SC for delivery of a weak electrolyte by iontophoresis under a constant
electric field. It is known that as current will take the path of least resistance,
it will travel predominantly through the aqueous domain of the SC, meaning
drug permeating the lipoidal route will not be directly affected by current. In
this paper the authors consider diffusion, electroosmosis and electromigration in
the aqueous route and diffusion only through the lipid route. The Nernst-Planck
equation is used to describe movement in the aqueous domain with an additional
constant flux term included for electroosmosis. Drug is allowed to pass between
the lipid and aqueous domains dependent on partition coefficients and pH (which
affects ionisation). They found that diffusion via the lipid domain provided a
non-negligible contribution to overall delivery and demonstrate consistency with
experimental work. The results highlight the importance of pH and ionisation in
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partitioning and iontophoretic delivery of weak electrolytes.
Nugroho et al. consider an in vitro iontophoretic delivery set up, with skin
clamped between two cells [126]. In this paper electromigration and electroosmosis
are grouped together and referred to as an iontophoretic driving force (IDF).
They claim that although enhanced passive diffusion may not provide significant
contribution during iontophoresis, when iontophoresis has been stopped and there
is no IDF, enhanced passive diffusion becomes significant. This hypothesis is
explored by modelling the in vitro set up using two well mixed homogeneous
compartments, one representing the skin the other representing the acceptor
solution. The donor solution is not modelled, as it is assumed the concentration
here is constant. They consider two separate scenarios. In the first, movement into
the skin compartment is described by a zero-order influx rate constant from the
donor compartment driven by the IDF. Drug is then removed from the skin, with a
first order rate constant to the acceptor compartment described as a ‘skin release
rate constant’; in the second scenario they consider a similar two compartment
set up but alter the removal term from the skin to acceptor compartment, so
that it includes IDF (this remains a first order rate constant). The authors
go on to consider the post iontophoresis period in both cases. They find that
both models could be fitted to data for the iontophoresis and post-iontophoresis
period and that incorporation of the IDF in the ‘removal from skin’ term, in
the second model, didn’t improve the model fit. The authors claim that this
suggests a negligible iontophoretic driving force contribution in the mass transfer
from skin to acceptor compartment. However, it could be argued that, as the two
models are mathematically equivalent (apart from a step change in the parameter
value in question when the machine is turned off) that, although they have found
parameters that fit and provide good agreement with data, that clearance from
skin to acceptor compartment during iontophoresis may still be dependent on
the electromigration and electroosmosis. This could be tested by repeating the
experiment at different currents which, if their claim is correct, would see the
clearance rate from skin to acceptor compartment unchanged. They conclude that
drug delivery post iontophoresis into an acceptor compartment in vitro is well
described by a first order clearance term from the skin compartment.
Note that for the purpose of reverse iontophoresis (extraction) that enhanced
passive diffusion post iontophoresis will not have an effect as we assume that when
iontophoresis has stopped the pad is also removed.
Much of what is known about iontophoresis has been determined from in vitro
studies in which a skin (SC) sample is clamped between two cells filled with buffer
solution used to replicate the pH of the body and donor solution. In vivo however,
electrodes are placed next to each other, not on either side of the membrane. Lai
et al. explore the in vivo set up using a mathematical model and consider both
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vertical and lateral transport [113]. In this paper, skin is modelled as a set of well
stirred compartments, where movement out of each compartment is described by
a ‘clearance’ term based on the Nernst-Planck equation. The model considers the
set up at “moderate time” i.e. after a pseudo steady state is reached. Their results
predict that lateral transport in the SC during iontophoresis is minimal. This is
supported by experimental work in the same paper which uses iontophoresis on
rats with cells spaced at 2 and 7cm. It is found that the concentration of a given
substance decreases exponentially with distance from an electrode.
4.4 Model Formation
We consider two electrodes connected to ‘collection pads’ on the skin surface, with a
fixed current passed between them, and create a model to describe the movement
of a positively charged molecule from the SC and plasma towards the cathodal
collection pad, see Figure 4-4. We assume that the separation between pads is
sufficiently large such that current doesn’t directly travel between the two via the












Figure 4-4: Schematic for reverse iontophoresis showing the movement of drug
from and through the aqueous domain of the SC (dashed arrows) and from the
lipid domain (wavy dotted arrows). The bold box highlights the area of interest
which is modelled in Subsection 4.4.
It has been shown that on application of an electric field, aqueous pathways
‘open up’ in the SC and these are the main route of current through the SC. We
therefore consider the SC constituent ‘aqueous’ and ‘lipid’ domains. In the aqueous
domain we expect ionised drug to move via electromigration, electroosmosis and
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Figure 4-5: Simplified schematic for reverse iontophoresis model set up. The top
compartment represents the collection pad, the middle compartment, x = 0 to
x = L, represents the SC which is separated into lipid and aqueous domain with
k7 representing the reversible movement between lipid and aqueous domains, and
the bottom compartment represents the plasma from model 1 (Chapter 2). Full
details of the model are provided in Section 4.4 - 4.6
diffusion. As current takes the path of least resistance (aqueous domain) we don’t
expect the movement of solute in the lipid domain to be directly affected by the
current. However, as discussed in Section 4.2.5, there may be some increase in
passive diffusion during iontophoresis. Therefore, the only movement mechanism
in the lipid domain is passive diffusion. Any enhancement in passive diffusion is
accounted for by an increase in the diffusion coefficient. Movement between the
two domains is accounted for via a partitioning term, represented by horizontal,
reversible arrows in Figure 4-4.
The experimental set up in Figure 4-4 is simplified in Figure 4-5 to show the
model layout. Here, plasma is taken as a single homogeneous compartment which
provides boundary conditions at x = 0 for the spatial SC compartment. As only a
small amount of drug is extracted during reverse iontophoresis we assume drug in
the plasma is not depleted by the process. We also initially assume that the drug
concentration of plasma does not change significantly during the time period of
reverse iontophoresis. We therefore take the plasma concentration to be constant.
Electromigration is modelled using Faraday’s law of electrolysis as detailed in
Section 4.2.3. We therefore also consider the movement of sodium, chloride and
potassium ions as these are the most abundant in the SC and are likely to be the
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main charge carriers [24]. Though other ions are present, these are at a much
lower concentration so we consider competition with them to be negligible. We
assume that due to their abundance and the comparatively small amount collected
by reverse iontophoresis there is no notable depletion of sodium, chloride and
potassium ions during the sample period due to reverse iontophoresis.
As electroosmosis is independent of the molecule being transported, it is taken to
be a constant experimentally determined flow rate, proportional to the current.
Let Cid(x, t) denote the concentration of ion i in domain d at time t, at position x
in the SC, where x = 0 is the base of the SC and x = L is the SC-collection pad
interface.
Flux of drug in the aqueous domain (pores) of the SC is therefore given by the sum
of flux due to enhanced passive diffusion, electromigration and electroosmosis,






where Jiaq denotes the flux (mols
−1) of ion i in the aqueous domain of the SC,
Diaq is the diffusion coefficient of ion i in the aqueous domain, I is the current
intensity, ti is the transport number of ion i, F is Faraday’s constant, zi is the























As we assume the change of concentration of Na+, Cl−, K+ over the period
of reverse iontophoresis is negligible and that the concentration of the drug of
interest is small compared to the concentration of Na+, Cl−, K+, we assume that
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where Dlip is the diffusion coefficient in the lipid. As we are considering the
concentration of only one drug, we drop the ‘i’ and write Ciaq = Caq, Cilip =
Clipwith zi = z, µiaq = µaq, Diaq = Daq, Dilip = Dlip. Incorporating movement






















+ f(Caq, Clip). (4.29b)
where
f(Caq, Clip) = k7(Caq − faq(Clip + Caq))
with faq the fraction of drug in the aqueous domain at equilibrium and k7 the rate
at which drug moves between the lipid and aqueous domains.






Jlip|x=L + Jaq|x=L dt
where Jlip|x=L and Jaq|x=L are the flux of ions at x = L in the lipid and aqueous
domains respectively.
4.5 Boundary Conditions
At x = 0 (base of the SC) the only movement into the SC is the drug being pulled
through from the plasma due to iontophoresis (electromigration, electroosmosis
and enhanced passive diffusion) and only unbound drug is extracted via reverse
iontophoresis. Drug entering the SC due to desquamation (as in Model 2, Chapter
3) happens on a much longer time scale than iontophoresis and contribution from
this is therefore negligible. We therefore have the the boundary condition in the
aqueous domain at x = 0 given by
Caq(x = 0, t) = βPu (4.30)
where β is the partitioning coefficient and Pu is the concentration of unbound drug
in the plasma.
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At x = L, as the collection pad has a comparatively large volume to the SC and
we assume it is replaced regularly during the iontophoretic extraction, we impose
infinite sink conditions at the boundary x = L for both the lipid and aqueous
domains and we therefore have
Ciaq(x = L
+, t) = 0, (4.32)
Cilip(x = L
+, t) = 0. (4.33)
4.6 Initial Conditions
Only unbound drug is available to be extracted via reverse iontophoresis [25].
Initial conditions consist of a spatial reservoir profile. In the full model system
(explored in Chapter 5) initial conditions are given by the unbound reservoir size
at the time of extraction (end time of reservoir formation= t0) distributed between
the lipid and aqueous domain as according to the prescribed value of faq. For the
purpose of exploration in this chapter, we consider a uniform distribution of drug
in the reservoir prior to extraction given by
C(x = [0, L], t = t0) = C0,
distributed between the lipid and aqueous domains depending on the value of faq
such that
Ciq(x = [0, L], t = t0) = faqC0, (4.34)
Clip(x = [0, L], t = t0) = (1− faq)C0. (4.35)
4.7 Numerical Scheme for Model 3
We seek to solve the system of equations (4.29) with boundary conditions (4.30)-
(4.33) and initial conditions (4.34), (4.35) numerically.
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We first consider the simplified system where f(Caq, Clip) = 0 so there is no

























We start by discretising the domain x ∈ [0, L] using a uniform mesh on N points
with mesh width ∆x = L/N .
Define C := Caq,U := Clip, we can then approximate (4.36a) using
(Ci)t = Daqδ
2Ci − vδ−Ci,
where (Ci)t denotes the time derivative of C (Caq) at spatial point xi := i∆x, δ
2
denotes the standard finite difference approximation for the second derivate given
by
δ2Ci =
Ci+1 − 2Ci + Ci−1
∆x2
,






This is known as backwards difference and is used in this case due to the direction
of the advection (from x0 to xN ).
We write this in matrix form as
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−2 1 0 . . 0
1 −2 1 .
0 1 −2 1 .
. . . . 0
. . . .
0 . . 0 1 −2

Ci + b (4.37)





1 0 . . 0
−1 1 .
0 −1 1 .
. . . 0
0 . 0 −1 1
Ci.
Next we need to take account of boundary conditions. At x = 0 for the aqueous
domain we take C0 = βPu
(C1)t = Daq
(









we therefore need to add
DaqPu
∆x2
+ vPu∆x into the first entry of the boundary condition
vector, b.
At x = L for the aqueous domain we have infinite sink conditions (for the diffusion)
(CN )t = Daq
(









as we have an up-winding scheme, advection is already taken care of. We have
sink conditions on the right-hand side (RHS) and so set CN+1 = 0, therefore the
RHS boundary conditions are already taken care of by our matrices δ− and δ2.
Following the same procedure for the lipid domain we have
(Ui)t = Dlipδ
2Ui.
At x = 0 in the lipid domain we have zero diffusion and so we let C0 = C2. We
therefore change the matrix for δ2 (equation (4.37)) to
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−2 2 0 . . 0
1 −2 1 .
0 1 −2 1 .
. . . . 0
. . . .
0 . . 0 1 −2

Ci. (4.38)
At x = L in the lipid domain we again have sink conditions. Finally we reintroduce
movement between the aqueous and lipid domains.










Ct = AC + b
A = Daqδ
2 − vδ− − νI
where I is the n× n identity matrix and ν = k7(1− faq)









where µ = k7faq.
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the vector of boundary conditions.
4.8 Nondimensionalisation
We wish to explore the dependence of drug collected on the parameters in the
system because exact parameter values are not all available in the literature, and
those that are are subject to error due to assumptions made in their approximation
(the radius of a molecule is required when estimating the diffusion coefficient of the
molecule, for example, and this is estimated under the assumption that molecules
are spherical which is not often the case). We choose to rescale the system so that
























+ f(Ciaq, Cilip). (4.39b)
where f(Ciaq, Cilip) = k7(Ciaq − faq(Cilip + Ciaq)).
We then nondimensionalise the concentration by C0, the average (lipid + aqueous)
initial reservoir concentration over x and the time by L/v; the characteristic time
scale for drug to cross the stratum corneum by advection alone. Hence equation














+ k7(Ciaq − faq(Cilip + Ciaq))). (4.40b)
Ciaq(x¯ = 1, t¯) = 0, (4.41)
Cilip(x¯ = 1, t¯) = 0. (4.42)
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First we explore the impact of the inclusion of a lipid compartment on the predicted
drug extracted. In order to do this we consider the system (4.29) in the case where
the diffusion coefficient in the lipid and aqueous domains are zero (diffusion free
case). We solve equations numerically for the cases
i) reservoir entirely in aqueous domain (faq=1)
ii) reservoir distributed between the aqueous and lipid domain (faq=0.6) with k
large (equilibrium between aqueous and lipid reached quickly) and
iii) reservoir distributed between the aqueous and lipid domain (faq=0.6) with k
small (equilibrium between aqueous and lipid reached slowly).
A value of faq = 0.6 is chosen for illustrative purposes in the cases ii) and iii) so
that values for the lipid and aqueous domains can be easily distinguished. The
results shown here are qualitatively representative of results for 0 < faq < 1.
The total reservoir concentration over time in each case is shown in Figures 4-6(a)-
4-6(c). The amount collected on the pad over time for each case i)-iii) is presented
in Figure 4-7(a) with the case where the reservoir is initially empty (relating to a
drug na¨ıve patient) also shown for comparison. The information in Figure 4-7(a)
is also given as a histogram of extracted fluxes in half hour intervals in Figure
4-7(b),this mimics the data that would be collected in a reverse iontophoresis
experiment, where the collection pad is typically changed every half hour and the
total drug on each pad measured.
The model results are as follows
i)If all the drug in the stratum corneum is in the aqueous domain it is readily
available for extraction. Therefore the reservoir is completely emptied before
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readings begin to reflect plasma concentrations (Figures 4-6(a),4-7(a)) and the
reservoir size can be easily distinguished.
ii)If only a portion (60% in this example) of the drug is in the aqueous domain,
the reservoir isn’t immediately emptied and we see a much smaller initial reading
Figure 4-7(b). In this case the reservoir size is more difficult to distinguish
as subsequent readings reflect a combination of plasma concentration and the
emptying lipid reservoir.
iii)In the case where the drug is distributed between the aqueous and lipid
compartments and equilibrium between these compartments is slow (Figure 4-
6(c)) we again see a smaller initial reading. Estimation of the total reservoir size
is arguably more difficult if faq is unknown, as it is not clear from subsequent
readings whether the reservoir has been emptied (Figure 4-7(b)), this could also
lead to over prediction of plasma concentration.
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(a) faq = 1
(b) faq = 0.6, fast
(c) faq = 0.6, slow
Figure 4-6: Unbound drug concentration in the lipid and aqueous domains of the
SC during extraction shown for: a) faq=1, b)faq=0.6, k7=2 (large), and c)faq=0.6,
k7=0.1 (small). 91
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(a)
(b)
Figure 4-7: Amount of drug extracted over time for the cases: faq=0.6, k7 large,
(yellow); faq=0.6, k7 small, (green); faq=1 (red) and the reservoir free case (blue).
Shown as the continuous extraction over time (top) and as extracted flux in
iontophoresis intervals (bottom).
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4.9.2 Diffusive flux included
Initially we consider the aqueous only case. The dependence on diffusion is shown
for extraction times t¯ ∈ [0, 3] as the impact of the diffusion coefficient displays
time dependence. We show results for values of D¯aq ∈ [0, 1.5]. From Figure 4-8
we can see that at small times, non-zero diffusion < 1 hinders the movement into
the collection pad. This means that results observed in iontophoretic extraction
for small, non zero diffusion coefficient will have a smaller initial peak than in
the diffusion free case. What we observe here is that the introduction of diffusion
reduces the clarity in change between extracting reservoir and extracting plasma
drug.
Figure 4-8: Dependence of amount of drug extracted on diffusion for different
extraction times using the nondimensional model with faq = 1, k7 = 0, Pu=0.2,
Cu(t = 0)=1.
Comparing the impact of the diffusion in the lipid and aqueous domains we again
consider the nondimensional system (4.40). Drug accumulated on the collection
pad in time t¯ = 1 is given in Figure 4-9 for values of D¯lip and D¯aq ranging from 0
to 0.5. This graph shows that the presence of diffusion in the lipid domain has a
greater impact on drug collected than diffusion in the aqueous domain, and that
this contribution is consistently positive. Diffusion in the aqueous domain can
increase or reduce drug collected for small times depending on the value of D¯aq as
seen in Figure 4-8.
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Figure 4-9: Dependence of amount of drug extracted on diffusion coefficient in
aqueous and lipid domains for the nondimensional model. The graph shown is for
the case faq = 0.5, k7 = 0.1 (C0 = 1, Pl = 0.2). The results for other values of k7
and faq are qualitatively similar.
4.10 Conclusion
In this chapter (reverse) iontophoresis and the mechanisms involved have been
described, with equivalence demonstrated between the Nernst-Planck equation and
Faraday’s law of electrolysis for electromigration. Models for drug delivery via
iontophoresis are reviewed with a focus on the approach to modelling the SC
structure. Accordingly we have created a 1D spatial model for the extraction
of a reservoir in the SC via reverse iontophoresis. The model created for reverse
iontophoresis builds on the model for reverse iontophoretic extraction by Paulley et
al. [24] by incorporating SC structure and mechanisms identified in the literature
on iontophoretic delivery. Our model considers a SC comprised of a lipid and an
aqueous domain with diffusion in the lipid and electromigration, electroosmosis and
diffusion in the aqueous domain, with partitioning between the two domains. This
has not been done for reverse iontophoresis previously. Using the spatial aspect of
the model we also incorporated the fact that the pathway of drug from plasma to
the collection pad is through the stratum corneum. Our model is therefore able
to capture the lag behaviour for the reservoir-free case which has not previously
been achieved.
The results show that the distribution of the reservoir between the lipid and
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aqueous domain and the rate of partitioning between the two has a potentially
significant impact on the way that the reverse iontophoresis results are interpreted,
especially if the parameter values are not known.
For a drug where the diffusion coefficient in the lipid/aqueous domain is on a
comparable time scale to the extraction we expect that the distinction between
drug extracted from the SC and from the plasma will be less well defined.
The number of samples and frequency of collection pad replacement could be
optimised for the drug of interest by determining the lag time for the reservoir-free
case to optimise the distinction between SC and plasma extraction. Ideally if lag
time is not known the sample frequency should be as often as possible, however,
as we are expecting only a small amount to be collected in each sample and this
needs to reach a minimum value for quantification this may not be a practical
solution in vivo. Sampling should also be continued until a steady extraction flux
is obtained to maximise the chances of the reservoir being completely extracted
and to be confident that the steady flux relates to the plasma concentration.
In this model we have assumed that the resistance, and therefore diffusion and
mobility (which affects electromigration), remain constant in the SC over the
period of reverse iontophoresis. It has, however, been shown that this is unlikely
to be the case (Subsection 4.2.5). If resistance in the SC were to change during
extraction, the reservoir may be over or under predicted by our model.
We have also made the assumption that the drug is 100% ionised in the SC.
Ionisation and pH effects could be incorporated by following a similar procedure
to Imanidis and Luetolf [120] who also consider that partitioning between lipid
and aqueous compartments may be dependent on ionisation and pH.
We believe that the model for reverse iontophoresis presented here provides a
convincing case for experimental work to be carried out to answer questions





In this chapter we combine models for systemic drug concentration, reservoir
formation and extraction from previous chapters to create an integrated model
system. The model takes a prescribed dose regimen for a given drug over a set time
period and predicts the resulting plasma concentration profile, the accumulation
of that drug in the SC, and the reverse iontophoresis extraction fluxes. The
objectives of this chapter are to bring together the work in previous chapters,
to compare the predictions of the model system with data from the literature,
to determine which factors from each model have the most significant impact
on reverse iontophoresis readings, and what that impact is, and to explore the
potential for reverse iontophoresis as a compliance monitoring technique.
We start with a brief review of the literature, with a focus on combination
of transdermal delivery and PK models. The model system is adapted to
lithium which exhibits straightforward physio-chemical properties so that model
predictions can be compared with data from the literature. Using parameter
estimates obtained for the lithium case we explore the more complex physio-
chemical scenarios built up in previous chapters and look at their effects on the
predicted reverse iontophoresis readings. Finally we explore the potential for
reverse iontophoresis as a compliance monitoring technique.
5.2 Literature review
There are a small number of papers that combine transdermal delivery of a drug
with the resulting systemic profile.
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Reddy et al. [119] combined a number of passive transdermal delivery (TDD)
models, developed in an earlier paper [136], with a one compartment systemic
PK model to examine the effects of changing vehicle and blood concentrations
and differences between the skin models chosen. In the first TDD model the
skin is described as a single well mixed compartment. In this model vehicle skin
and blood compartments are combined through a system of three ODEs, with
linear first-order transfer between the vehicle and skin, and the skin and blood
with a volume adjustment term for each. A constant boundary concentration is
given for the vehicle-skin interface and a constant flux condition at the blood-skin
interface. They conclude that, for short exposure times, the membrane model is
most accurate. However, in circumstances where time taken for drug to absorb
into skin is much shorter than exposure time, or when physical parameters are not
exactly known, compartmental models provide acceptable predictions.
Nugroho et al. created a set of mathematical models for iontophoresis in vitro
considering both the iontophoretic delivery and the resulting plasma profile [127].
They create four models: two models for drugs with one compartment elimination
kinetics, and two models for drugs with two compartment elimination kinetics.
The first model uses an ODE with a constant input rate from the skin and a
first order elimination rate constant. The second model considers a time variant
input which takes time dependent values of flux from the predicted clearance
from skin in their 2004 paper [126], discussed in Chapter 4. In the third and
fourth models an additional ‘peripheral compartment’ is added, into which drug
reversibly distributes according to first order rate constants. Again constant and
time dependent influx from the skin is considered. In both these cases the post-
iontophoretic phase is explored by assuming that after the electric current is turned
off, no further drug enters systemic circulation and so we have clearance only.
In the two compartment model, drug continues to distribute into the peripheral
compartment during the post iontophoresis phase and so elimination presents as a
biexponential decay. In this paper they demonstrate the value of inclusion of a time
varying input from the skin, which fits the iontophoresis and post iontophoresis
data significantly better in both one and two compartment cases. This scenario is
relevant to delivery where drug remains in the SC even after the device is removed
but an equivalent for the RI case isn’t obvious. As the models used are non-
spatial, joining together of skin and plasma compartments is done using transfer
rates between compartments.
A review paper by Grassi et al. considers mathematical modelling of simultaneous
drug release and in vivo absorption [137]. Both passive and iontophoretic delivery
are considered, with sink conditions used at the base of the skin for the passive
case and flux matching on the stratum corneum/viable skin boundary for reverse
iontophoresis to prevent drug accumulating there. Once the drug has entered the
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body model from the skin it does not re-enter the skin.
5.3 Comparison of model predictions with lithium
data
Given the lack of relevant data for our unknown mechanistic parameters, we exploit
data collected on lithium extraction via reverse iontophoresis to provide parameter
estimates to populate the models. Lithium is a useful drug in this context since it
is small, positively charged, does not bind and is not metabolised (i.e. parameters
are mostly known).
Detailed data for lithium monitoring via reverse iontophoresis is given in the
paper by Leboulanger et al. [15], which provided motivation for the preliminary
modelling work on reverse iontophoresis by Paulley et al. [24].
The study by Leboulanger et al. [15] involved 30 bipolar or schizo-affective
patients, each of whom had been receiving chronic lithium therapy at doses of
12-36 mmol/day for no fewer than 3 weeks. Reverse iontophoresis was carried out
on each patient for a period of 2 hours (four 30 minute intervals) using a collection
pad of area 3.2±0.4cm2 and a current of 0.8mA. A blood serum sample was taken
for comparison at 90-100 min after initiation of reverse iontophoresis.
Blood samples showed that around 75% of the patients had serum lithium
concentrations between 0.5-0.9mmol, which lie within the therapeutic range
(Figure 5-1). Data in Figures 5-2 and 5-3 taken from Leboulanger et al. [15]
show that extraction fluxes are greater within the first 30 minutes after which
they reduce to align with plasma drug concentrations.
5.3.1 Assumptions and model adaptions
In order to model the plasma profile, reservoir formation, and extraction for
lithium, we must make some adaptions to each of our three models. In the paper
by Paulley et al. [24] the only mechanism used to describe reservoir formation
is desquamation and the only mechanism for extraction is electromigration.
We start by replicating this approach with our spatial models and compare
the model predictions with data. We then reintroduce the mechanisms, where
appropriate, from the full model to explore the impact on model predictions;
diffusion in reservoir formation, diffusion and electroosmosis in extraction model
and separation into lipid and aqueous domains in extraction.
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Figure 5-1: Taken from Leboulanger et al. [15]. Shows the serum concentrations
of lithium for patients in the study. Note dotted lines indicate the ‘normal’ range.
Figure 5-2: Taken from [15]. Shows extraction fluxes of lithium over the four 30
minute extraction periods.
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Figure 5-3: Taken from [15]. Figures A-D are plots of extraction flux data for
iontophoresis extraction periods for each patient plotted against their plasma
concentration. A: extraction period [0-30] minutes, B: extraction period [30-60]
minutes, C: extraction period [60-90] minutes, and D: extraction period [90-120]
minutes.
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Model 1: Systemic Lithium
Lithium exhibits one compartment pharmacokinetics, therefore Model 1 will take
the same form as the model from Paulley et al. [24]. For a daily oral dose of






where L1(t) is the lithium concentration in the plasma, δ is the dose, ke is the
excretion rate and k is the absorption rate.
Initial conditions: We start with a drug naive patient and ‘administer’ a daily
dose of 24.3 mmol each day for 30 days to imitate the scenario in the study by
Leboulanger et al.[15].
L1(t = 0) = 0.
Model 2 : Reservoir Formation
We start with the simplest case and describe the formation of the reservoir in the
SC by desquamation only. We consider the SC in one dimension with x ∈ [0, L]






where L2(x, t) is the unbound lithium concentration in the SC (nmol/µm) directly
beneath the collection pad and v is the velocity of desquamation (µm/day).
Boundary conditions: If we have plasma concentration as L1(mmolL
−1) =
L1(µmolcm
−3) and we assume that there is a smooth flat interface between the
plasma and the SC at the base of the SC (x = 0) of area 3.2cm2, directly beneath
the collection pad of the same area, then the concentration on that interface is
given by
L2(0, t) = L1(t) · 3.2 · αµmol
cm
= L1(t) · 0.32 · αnmol
µm
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where α is a dimensionless parameter which represents a combination of a partition
coefficient and a correction factor to account for the assumption that plasma
directly connects with SC at a smooth, flat interface.
Initial conditions: As we are considering an initially drug naive patient, at
t = 0 we have initial condition
L2(x, 0) = 0.
Model 3: Reverse Iontophoresis of Lithium
L2(x, t) = L3(x, τ) where τ = 0 starts at t = 30.5 days. Since lithium is small and







where L3(x, τ) is the concentration of lithium in the SC (nmol/µm) directly
beneath the collection pad during extraction and vem, the velocity due to






where parameter definitions and values are given in Table 5.1.
The same assumption is made here as in Chapter 4: concentration of lithium in SC
is small compared to other ions present and so its contribution in the summation
in the denominator is assumed to be negligible.
Note the time variable is denoted τ in this model, this is because τ = 0 starts at
t = 30.5 days, 12 hours after the dose on day 30, and time during extraction is
measured in minutes, as this is an appropriate time scale for reverse iontophoresis.
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Parameter Definition Value Reference
δ Lithium dose 24.3mmol [24, 138, 15]
ke Lithium excretion rate 0.654day
−1 [24, 138]
k Lithium absorption rate 4.62day−1 [24, 138]
L SC thickness 18.3µm [95]
v Speed of desquaming skin 1.307µmday−1 [52, 53]
I Current density 0.25mAcm−2 [15]
F Faraday’s constant 96.487Cmmol−1 [15]
µNa Aqueous mobility of sodium 5.19× 10−4cm2s−1v−1 [118]
µCl Aqueous mobility of chloride 7.62× 10−4cm2s−1v−1 [24]
µK Aqueous mobility of potassium 7.91× 10−4cm2s−1v−1 [118]
CNa Concentration of Na in the SC 32.7× 10−3mmolcm−3 [139, 140]
CCl Concentration of Cl in the SC 61× 10−3mmolcm−3 [139, 140]
CK Concentration of K in the SC 91× 10−3mmolcm−3 [139, 140]
µLi Aqueous mobility of lithium 4.01× 10−4cm2s−1v−1 [118]
vem Velocity due to electromigration 4.602µmmin
−1 [125, 25, 19]
Table 5.1: Parameter estimates used for Lithium models
Boundary conditions: We assume plasma concentration remains unchanged
during extraction and take the boundary condition at x = 0 as the plasma
concentration 12 hours after the dose on day 30, adjusted for area, given by
L3(0, τ) = L¯1(t = 30.5) · α
where α=0.32.
Initial conditions: At the start of reverse iontophoresis we have a reservoir
given by the Model 2 reservoir prediction at t = 30.5
L3(x, τ = 0) = L2(x, t = 30.5)
5.3.1.1 Results and discussion
Model 1
The predicted plasma profile for a daily dose of lithium starting at t = 0 is given
in Figure 5-4. This model has been replicated from [24] and the results obtained
are identical to results given in that paper. The predicted plasma profile ‘steady
state’ concentration is within the range specified in the paper by Leboulanger et
al. [15].
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Model 2
The predicted accumulation of lithium in the SC, scaled to the area of the collection
pad, is given in Figure 5-5. In this case, movement into and through the SC was
modelled by a constant advection rate representing desquamation. The value for
partitioning of lithium from plasma into the SC is unknown. The area of the
interface between plasma and stratum corneum beneath the collection pad was
approximated to be 3.2cm2 (the same area as the interface between SC surface
and the collection pad). In reality there is no such direct interface and even then
it is unlikely to be smooth and flat. Therefore α is a combination of the unknown
partition coefficient and an adjustment factor to account for this approximation.
The value of α has been chosen so that the resulting reservoir size reflects that
observed reservoir size from the data. This is a weakness in our model as exact
reservoir size can’t be determined from the data in Leboulanger et al. [15]. This
identifies the need for further experimental work to determine the actual reservoir
size (discussed in detail later). The prediction for the drug concentration in the SC
given by Model 2 (equation (5.2)) qualitatively agrees with the model in Paulley et
al. [24], increasing steadily before reaching a steady state value after 15-20 days.
Taking reverse iontophoretic extraction at 30 days, therefore, should give the same
predicted extraction as that for much longer term compliance.
Model 3
The predicted extraction of lithium is given as a continuous time profile in Figure 5-
6(a) and the same results are presented as a cumulative extracted flux in 30 minute
interval in Figure 5-6(b) for comparison with data given in [15] (shown in Figure
5-2). Comparing the predicted extraction in the final two intervals ([60-90], [90-
120]) with the observed extraction for these intervals, good agreement is obtained.
However the predicted initial extraction peak is too high and the equilibrium with
plasma is reached too quickly: within the first interval rather than the observed
[30-60] interval. In fact, on inspection of the continuous data the equilibrium with
plasma is reached in about 4 minutes, suggesting that the model predicts that the
reservoir is emptied too quickly.
The model for extraction (equation (5.3)) dictates that the time to empty the
reservoir (when the whole reservoir is available) is determined by vem and L. So we
hypothesise that possible causes of the short lag time could be an an overestimate
of the speed due to electromigration, vem, or an underestimate of the path-length
of extraction, L.
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Figure 5-4: Predicted plasma concentration for a fully compliant patient on a daily
dose of lithium described by equation (5.1).
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Figure 5-5: Predicted reservoir size over time in the SC directly beneath the
collection pad (area 3.2cm2 as specified in Leboulanger et al. [15] experimental
protocol) using equation (5.2).
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(a)
(b)
Figure 5-6: Extraction prediction for lithium presented as a continuous cumulative
amount collected against time and cumulative extracted flux in each iontophoresis
interval for comparison with data (Figure 5-2). Predictions as per equation (5.3)
with L = 18.3, vem= 4.602µmmin
−1 Table 5.1.
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5.3.1.2 Altering the advection value
Estimation of vem from the literature is certainly subject to a range of parameter
uncertainties and approximations. One option is to choose vem to obtain a lag
time as observed in [15]. If we assume that all reservoir of drug is immediately
available for extraction, Figure 5-2 (from [15]) would suggest it takes between 30
and 60 minutes to cross the SC from the plasma. Taking the midpoint and keeping





which results in the model predictions shown in Figure 5-7, providing a good
agreement with the lag time but a significant underestimate of plasma extraction
in the intervals 60-90 min, 90-120 min.
5.3.1.3 Altering extraction path length
Alternatively the observed lag time could be increased by increasing the extraction
path length. Reasonable agreement with extraction data (lag time within the 30-60
minute interval) is achieved with only a 10 fold increase in extraction path length,
Figure 5-8, without altering the rate at which drug is extracted from the plasma
in intervals 60-90 min, 90-120 min. This is done by increasing the extraction path
length and redistributing the total reservoir, as predicted by Model 2, over this
new space prior to extraction. An increase path length (i.e. tortuosity) of 10 fold
does not seem unreasonable when considering the tortuosity of the intercellular
route through the SC (as discussed in Chapter 3) has been shown to be as much
as a 50 fold increase [86]. Whilst we interpret increased path length as introducing
a more tortuous route through the SC; the route could alternatively include the
subcutaneous tissues or lower layers of skin. To consider this would require model
adaption including an intermediate compartment between plasma and SC which
we don’t consider here.
5.3.2 Potential for monitoring compliance
Using this model for lithium, with an increased path length during extraction, we
explore detection of compliance via reverse iontophoresis. To do this we create the
following four compliance scenarios
(a) Daily dose of 24.3mmol lithium for 30 days (fully compliant)
(b) Dose of 24.3mmol lithium every other day for 30 days
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(a)
(b)
Figure 5-7: Extraction prediction for lithium presented as a continuous cumulative
amount collected against time and cumulative extracted flux in each iontophoresis
interval for comparison with data (Figure 5-2). Predictions using equation (5.3)
with L=18.3, vem= L/45 as discussed in section 5.3.1.2.
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(a)
(b)
Figure 5-8: Extraction prediction for lithium presented as continuous cumulative
amount collected against time and cumulative extracted flux in each iontophoresis
interval for comparison with data (Figure 5-2). Predictions using equation (5.3)
with L=183 as discussed in section 5.3.1.3 and vem= 4.602 µmmin
−1 (Table 5.1).
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(a) Compliance scenario a (b) Compliance scenario b
(c) Compliance scenario c (d) Compliance scenario d
Figure 5-9: Plasma concentrations for compliance scenarios (a)-(d), as described
in the text.
(c) Daily dose of 24.3mmol lithium every day for 29 days with a missed dose on
day 30
(d) Daily dose of 24.3 mmol lithium on days 24- 30
Note that these scenarios have been selected as they are representative of
traditional compliance monitoring via a blood sample at day 30, and should
return similar compliance predictions for scenarios (a) and (d), and scenarios (b)
and (c) despite significantly differing levels of compliance between them. The
predicted plasma profiles for compliance scenarios (a)-(d) are given in Figure 5-9.
Throughout this chapter plots relating to scenario (a) will be shown in green, (b)
in dark pink, (c) in blue and (d) in yellow for ease of comparison.
The reservoirs corresponding to compliance scenarios (a)-(d) as predicted by
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Figure 5-10: Predicted lithium reservoir in the case of no binding and no diffusion
i.e. cell renewal only. Shown for the four compliance scenarios: (a) Compliant
(daily dose for 30 days); (b) habitual non-compliance (dose every other day for 30
days); (c) missed dose on day 30; (d) doses start on day 24.
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Figure 5-11: Predicted extraction for the lithium model for the four compliance
scenarios: (a) Compliant (daily dose for 30 days); (b) habitual non-compliance
(dose every other day for 30 days); (c) missed dose on day 30; and (d) doses start
on day 24. (no diffusion). Path-length of extraction is adjusted as discussed in
subsection 5.3.1.3 (L = 183µm).
113
CHAPTER 5. MODEL COMBINATION
equation (5.2) are given in Figure 5-10. Comparing these with the plasma con-
centrations at day 30 in Figure 5-9 we can see that although compliance scenarios
a and d have the same plasma concentration, the reservoirs differ significantly.
Again compliance scenarios b and c have similar plasma concentrations but, due
to their compliance history, a different reservoir size.
The predicted extraction fluxes for all four compliance scenarios, via electromigra-
tion with an increased path length, are given in Figure 5-11. Scenarios a, b and
c give a qualitatively similar profile (initial peak followed by lower extraction).
To determine compliance from data like this would have to be comparative and
sufficient data are needed to make accurate predictions. The extraction profile for
scenario d gives an initially small extraction followed by a peak which then reduces.
This is because dose was only administered in the last 7 days which means that
the reservoir is located towards the base of the SC.
5.3.3 Inclusion of other model mechanisms for lithium
So far we have considered the simplest case scenario in each model. Now we
reincorporate model mechanisms applicable to lithium in each model to inspect
the impact of their inclusion.
5.3.3.1 Distribution of reservoir into lipid and aqueous domains
The predictions for extraction given in Figure 5-6 identifies a need for model
adjustment. An alternative to the two suggested solutions (adjustment of vem
or L) is to reintroduce the division of the unbound reservoir into lipid and aqueous
domains during extraction, as described in Chapter 4. As current passes through
the aqueous domain it is from here that drug is extracted. Therefore introducing
this division means that not all drug is available for immediate extraction and
therefore a delay will be observed.
Reintroduction of this distribution for some arbitrary choice of unknown para-
meters k7(=1.4) and faq(=0.11), gives the predicted extraction in Figure 5-12, it
gives good qualitative and quantitative agreement with the data for path length
L = 18.3µm (stratum corneum thickness).
5.3.3.2 Diffusion in reservoir formation for lithium
Lithium is a small, mobile ion which means it has a large aqueous diffusion
coefficient. Lithium also doesn’t bind within the body and so it is likely that
lithium will diffuse in the SC during reservoir formation. We therefore reintroduce
114
CHAPTER 5. MODEL COMBINATION
(a)
(b)
Figure 5-12: Extraction prediction for lithium presented as continuous cumulative
amount collected against time and cumulative extracted flux in each iontophoresis
interval for comparison with data (Figure 5-2). Predictions using model (5.3) with
L=18.3, vem=4.602 as given in Table 5.1. With division into lipid and aqueous
compartments reintroduced for extraction with faq = 0.11, k7 = 1.4
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where D is the diffusion coefficient and v is the velocity of desquamation.
Figure 5-13 provides a comparison of the predicted formation of a lithium reservoir
in the SC for different values of diffusion coefficient, D, and for the diffusion- free
system. From this we can see that the reservoir formation with the theoretical
lithium diffusion coefficient is much more sensitive to plasma concentration
oscillations; the reservoir is quicker to fill and more sensitive to change. For small
non-zero diffusion we actually see an increase in time to reach steady state, this is
consistent with the findings in the Chapter 3 exploration (Figure 3-10). Provided
sufficient time has passed, the diffusion free case essentially gives the average
reservoir size. It is unlikely that this degree of fluctuation would be detectable, but
as discussed in Chapter 3 it may have a more significant impact when considering
non-compliance.
5.3.3.3 Electroosmosis and diffusion in reverse iontophoresis









where vRI = vem + veo
We introduce sink conditions on the boundary at x = L,
L3(x = L, t) = 0,
The re-inclusion of electroosmosis in the extraction of lithium is mathematically the
same as increasing the electromigration as these both make up the advection term
for extraction. This results in a shorter lag time and increased plasma extraction.
Due to the sink conditions at the skin surface, the re inclusion of diffusion during
extraction increases the speed at which lithium is transported across the SC, the
result of including diffusion is therefore similar to increasing the advection .
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Figure 5-13: Reservoir size in the SC in the area directly beneath the collection
pad predicted by equation (5.4) for different values of diffusion: (i) D = 0 (no
diffusion, blue line); D = 7588µm2/day (aqueous diffusion coefficient of lithium,
orange line); (ii) D = 1Lv (’critical diffusion, yellow line); and (iii) D =
0.1
Lv (small
diffusion, deep pink line).
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5.4 Theoretical drug
The key parameters and mechanisms of interest identified in the previous chapters
are binding and distribution of the reservoir between lipid and aqueous domains.
As mentioned previously, lithium does not bind. We therefore use a theoretical
drug based on lithium data, with which we explore model mechanisms not
applicable to lithium.
We are interested in the possibility of detecting non-compliance through reverse
iontophoresis. We bring forward the four compliance scenarios and create reservoir
and extraction predictions for various parameter sets to determine which, if any,
drug properties allow for compliance to be clearly distinguished from the extraction
predictions.
First we reintroduce binding in the SC and consider the reservoir formation in
compliance scenarios a-d for a number of binding and diffusion values.













− µCb + γCu, (5.6)
where Cu(x, t) and Cb(x, t) are the concentration in the SC (mol/µm) for unbound
and bound forms of the theoretical drug, D is the diffusion coefficient, v is the speed
of desquamation µ is the rate of unbinding and γ is the rate of binding.
As discovered in Chapter 3, the effects of binding during reservoir formation are
intertwined with the effects of diffusion, as this is what differentiates movement
of bound and unbound drug. We compare diffusion (of the magnitude predicted
for lithium in water) and the diffusion-free case, and for each of these we consider
γ > µ and γ < µ.
This creates the four binding cases given in Table 5.2.
The resulting reservoir predictions for the binding sets 1-4 are given in Figures
5-14 to 5-17 respectively, for each compliance scenario (a)-(d). From comparison
of these we can see that the ratio of bound to unbound drug in the reservoir is
determined by the ratio of γ to µ. When considering bound and unbound drug,
the magnitude of the unbound reservoir depends on the value of the diffusion
coefficient chosen. A larger diffusion coefficient results in larger oscillations and
larger reservoirs. This is because a large diffusion rate results in quick equilibration
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Parameter set D γ µ
Binding set 1 7588µm2day−1† 5day−1 1day−1
Binding set 2 7588µm2day−1† 1day−1 5day−1
Binding set 3 0 5day−1 1day−1
Binding set 4 0 1day−1 5day−1
Table 5.2: The four binding parameter sets used in Model 2 used with the L and v
estimates given in table5.1. † theoretical diffusion coefficient calculated for lithium.
with plasma concentration and presence of binding acts as a ‘storing mechanism,’
so, as plasma concentration decreases (during daily fluctuations), drug which is
‘stored’ as bound drug doesn’t diffuse to areas of low concentration. In Figures 5-
14 and 5-15, at 12 hours after the day 30 dose, the predicted unbound reservoir size
is similar for all four compliance scenarios with scenario b and c slightly lower than
a and d. This is due to the high diffusion coefficient which means that reservoir
size is quick to reflect plasma concentration change. In binding cases 3 and 4
shown in Figures 5-16 and 5-17 compliance could be easily distinguished with full
knowledge of the reservoir size. Comparing Figures in 5-16 and 5-17 we see that a
high rate of binding reduces the observable (unbound) reservoir.
5.4.1 Extraction
We wish to determine which parameter combination, if any, provide predictions for
compliant and non-compliant patients that can be easily distinguished. This will
help to identify potentially suitable drug candidates for this type of monitoring.
For the extraction we consider the reservoir to be distributed between a lipid
and aqueous domain and assume extraction is from the aqueous domain via










f(Caq, Clip) = k7(Caq − faq(Clip + Caq))
with faq the fraction of drug in the aqueous domain at equilibrium and k7 the rate
at which drug moves between the lipid and aqueous domains.
The drug collected on the pad at x = L is then given by
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(a) Compliance scenario a (b) Compliance scenario b
(c) Compliance scenario c (d) Compliance scenario d
Figure 5-14: Predicted reservoir formation using binding parameter set 1, Table
5.2, presented for bound and unbound drug in each compliance scenario a-d as
described in the text.
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(a) Compliance scenario a (b) Compliance scenario b
(c) Compliance scenario c (d) Compliance scenario d
Figure 5-15: Predicted reservoir formation using binding parameter set 2, Table
5.2, presented for bound and unbound drug in each compliance scenario a-d as
described in the text.
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(a) Compliance scenario a (b) Compliance scenario b
(c) Compliance scenario c (d) Compliance scenario d
Figure 5-16: Predicted reservoir formation using binding parameter set 3, Table
5.2, presented for bound and unbound drug in each compliance scenario a-d as
described in the text.
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(a) Compliance scenario a (b) Compliance scenario b
(c) Compliance scenario c (d) Compliance scenario d
Figure 5-17: Predicted reservoir formation using binding parameter set 4, Table
5.2, presented for bound and unbound drug in each compliance scenario a-d as
described in the text.
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where Jaq|x=L is the flux of ions from aqueous domain at x = L. As discussed
previously, the location of the reservoir may significantly impact the way in which
reservoir is extracted. We therefore consider two reservoir distributions; drug
completely in the aqueous domain and drug distributed between aqueous and lipid
domains with faq=0.1 (i.e. 10% of drug in aqueous domain at equilibrium). During
extraction drug is removed from the aqueous domain and we assume that as this
happens drug in the lipid domain will move into the aqueous domain in order
to maintain faq. The rate at which this happens will affect the amount of drug
available for extraction and the time in which it is extracted. We consider three
values of k7: 0.01, 0.1,1. Finally we construct initial conditions. Up until now we
have assumed that drug in the reservoir is initially distributed between lipid and
aqueous domains according to the value of faq. As described in Chapter 4 porous
pathways ‘open up’ on application of a current. Therefore these porous pathways
could be interpreted as a new space, initially containing no drug, which would
mean that all drug is initially in the ‘lipid’ domain whilst maintaining that at
equilibrium drug distributes between the domains according to faq. We therefore
also explore both of these initial conditions in the following experiments.
Results have been presented in a series of 9 figures, each containing 6 sub figures.
Figures 5-18 - 5-20 take faq = 1, with reservoir initially in the lipid domain,
Figure 5-18: initial reservoir size determined using binding parameter set 1,
Figure 5-19: initial reservoir size determined using binding parameter set 3,
Figure 5-20: initial reservoir size determined using binding parameter set 4.
Results for the extraction of the reservoir resulting from binding parameter set 2
have been omitted as the unbound reservoir size for binding sets 1 and 2 were the
same and so the same results were obtained.
The sub-figures show total collected and 30 minute cumulative extraction amounts
in the four compliance scenarios taking three values for k7, namely k7=0.01,0.1 and
1.
This pattern is repeated with the next three figure sets. Figures 5-21 - 5-23 take
faq=0.1, with reservoir initially in the lipid domain. Figure 5-24 - 5-26 take
faq=0.1, with the reservoir initially distributed between the lipid and aqueous
domain according to faq=0.1.
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Effect of k7 on predicted extraction From Figures 5-18 - 5-20 it is evident
that for faq = 1, where drug is initially in the lipid, an increase in k7 speeds up the
availability of the reservoir and therefore a higher, earlier extraction of the reservoir
is observed. However, when faq = 0.1, for both initial reservoir distributions, the
opposite is observed as drug that is pulled through the SC from the plasma moves
into the lipid domain and is not extracted. This unrealistic scenario is shown in
Figures 5-21 - 5-26.
Effect of faq on predicted extraction For faq=0.1 (Figures 5-21 - 5-26) we
notice a smaller extraction due to the reservoir of drug remaining in the lipid
domain and in cases of high k7 values, drug that is extracted from the plasma
moving into lipid domains.
Effect of ICs on predicted extraction When drug is not initially in the
pathway of extraction, a delay to extract the reservoir is observed dependent on
k7 and faq. Comparing Figures 5-21 with 5-24, 5-22 with 5-25, and 5-23 with
5-26 it can be seen that when some drug is initially in the pathway of extraction
(IC distributed according to faq) that marginally more drug is extracted overall.
It can also be seen that for small values of k7 the difference between compliant
and non-compliant extraction is more significant when the whole drug reservoir is
initially in the lipid. However, as we have already mentioned, the results in Figures
5-21 - 5-26, wherefaq=0.1, suggest that drug that is pulled through the SC from
the plasma by reverse iontophoresis gets stuck in the SC. We do not believe this to
be realistic and so any conclusions about initial conditions based on these results
should be made cautiously.
Compliance The only parameter set in all of these graphs where different
compliance scenarios gave distinct qualitative extractions is for parameter set:
faq=1, k7=1, binding parameter set 4: D = 0, γ = 1, µ = 5, Figure 5-20, i.e.
the scenario where drug is most available. This is because in all other cases the
release/extraction of the reservoir is moderated by the release from the lipid domain
and so differences in reservoir size are masked.
5.4.2 Optimal drug properties for extraction
The movement mechanism which dominates during reverse iontophoresis for a drug
molecule is dependent on properties such as valency (charge), ionisation, size, and
implicitly, on characteristics such as lipophilicity. It can be seen from transport
number equations that species with larger valency are better charge carriers and so
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Figure 5-18: Extraction of reservoirs for compliance scenarios a-d as predicted by
binding set 1 (Figure 5-14) with extraction parameters given by faq = 1, with
whole reservoir initially in the lipid domain at the start of extraction shown for
k7=0.01,0.1 and 1
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Figure 5-19: Extraction of reservoirs for compliance scenarios a-d as predicted by
binding set 3 (Figure 5-16) with extraction parameters given by faq = 1, with
whole reservoir initially in the lipid domain at the start of extraction shown for
k7=0.01,0.1 and 1
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Figure 5-20: Extraction of reservoirs for compliance scenarios a-d as predicted by
binding set 4 (Figure 5-17) with extraction parameters given by faq = 1, with
whole reservoir initially in the lipid domain at the start of extraction shown for
k7=0.01,0.1 and 1
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Figure 5-21: Extraction of reservoirs for compliance scenarios a-d as predicted by
binding set 1 (Figure 5-14) with extraction parameters given by faq = 0.1, with
whole reservoir initially in the lipid domain at the start of extraction shown for
k7=0.01,0.1 and 1
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Figure 5-22: Extraction of reservoirs for compliance scenarios a-d as predicted by
binding set 3 (Figure 5-16) with extraction parameters given by faq = 0.1, with
whole reservoir initially in the lipid domain at the start of extraction shown for
k7=0.01,0.1 and 1
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Figure 5-23: Extraction of reservoirs for compliance scenarios a-d as predicted by
binding set 4 (Figure 5-17) with extraction parameters given by faq = 0.1, with
whole reservoir initially in the lipid domain at the start of extraction shown for
k7=0.01,0.1 and 1
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Figure 5-24: Extraction of reservoirs for compliance scenarios a-d as predicted by
binding set 1 (Figure 5-14) with extraction parameters given by faq = 0.1, with
the reservoir initially distributed between the lipid and aqueous domains according
to faq at the start of extraction shown for k7=0.01,0.1 and 1
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Figure 5-25: Extraction of reservoirs for compliance scenarios a-d as predicted by
binding set 3 (Figure 5-16) with extraction parameters given by faq = 0.1, with
the reservoir initially distributed between the lipid and aqueous domains according
to faq at the start of extraction shown for k7=0.01,0.1 and 1
133
CHAPTER 5. MODEL COMBINATION
Figure 5-26: Extraction of reservoirs for compliance scenarios a-d as predicted by
binding set 4 (Figure 5-17) with extraction parameters given by faq = 0.1, with
the reservoir initially distributed between the lipid and aqueous domains according
to faq at the start of extraction shown for k7=0.01,0.1 and 1 . Note scenario (a)
is overlayed by scenario (c) on the 5th graph.
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have higher transport number, therefore presenting strong competition. However
electromigratory flux is inversely proportional to valence and so optimal delivery
is for a monovalent ion [104].




where η is the viscosity of the SC, ri is the radius of the ion and zi is the valency,
it is clear to see that small ions are more mobile and are therefore expected to
have a greater electromigratory flux. However, there is a link between diffusion





We want our ion to be highly mobile during the extraction phase so that we have
optimal electromigration. We have shown that diffusion of unbound drug during
the reservoir formation is disadvantageous for compliance monitoring as we want
a drug to enter the SC and stay put.
5.5 Conclusion and further work
In this chapter we have combined the work from the previous three chapters to
create a full model; from drug administration to reservoir formation and extraction
via reverse iontophoresis. We began by altering the model system for the case
of lithium where reverse iontophoresis data is available for chronically dosed
patients. Using parameter estimates from the literature our model gave reasonable
agreement with the lithium data, however, without further adaption of the model,
the true nature of the lag time was not captured. Three different solutions were
explored: reduction of the velocity due to electromigration; increased tortuosity for
extraction path length; and the division of the reservoir into a lipid and aqueous
domain so that not all drug in the reservoir is immediately available for extraction.
Any one or combination of these methods improves model fit but in order to
determine the scenario which best reflects reality more data are needed; specifically
continuous time data for reverse iontophoresis which would give an insight into the
way in which a drug reservoir is drained from the SC.
We went on to investigate the inclusion of other model mechanisms in reservoir
formation and extraction. We found that in order for a reservoir to contain the
maximal information on drug history (14 days) that a small diffusion coefficient is
needed. We also found that the presence of binding had potential to increase the
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total (bound + unbound) reservoir but had only a small impact on the magnitude
of unbound (extractable) reservoir if diffusion was present, consistent with the
exploration in Chapter 3. The preference for a drug with small diffusion coefficient
must be balanced with the demand for a highly mobile drug (i.e. high diffusion
coefficient) for efficient extraction via reverse iontophoresis.
Two possibilities for the location of the reservoir prior to extraction were
considered. The default assumption is that drug would be distributed between lipid
and aqueous domains according to the equilibrium distribution (faq). However, it
is thought that porous pathways open up on application of a current and so this
scenario was recreated by reservoir being completely located in the lipid domain
prior to extraction. On comparison with the default distribution we found that
if drug does not start in the pathway of the drug that this leads to less drug
collected overall. However, as we don’t believe results offer realistic predictions for
some of the parameter sets used, we restrain from concluding anything about the
distribution prior to extraction.
The research in this chapter demonstrates the potential for drug presence in the
skin to determine patient compliance to a drug regimen. However, more data
are needed to determine extraction profiles which are realistic for an individual
drug. Parameter estimates are difficult to obtain experimentally. Without accurate
estimates of parameter values there is no way of knowing if the reservoir is
completely emptied or not. Continuous time data could provide a much needed
insight, as could a comparison between whole skin sampling (biopsy or tape
stripping) and reverse iontophoretic extraction from the same patient. This is





Although reverse iontophoresis is an established technique, there is not a great
deal of usable (in vivo) data available in the literature to develop and validate
mathematical models. As described in Chapter 5, in order to improve interpret-
ation of experimental work in reverse iontophoresis a number of unknowns need
to be determined. Much of this could come from more reverse iontophoresis data
with different extraction time frames, but this does not guarantee determination
of parameters or unknown factors, such as where in the SC the reservoir resides.
In this chapter we explore alternative skin sampling techniques and investigate
their potential for use in monitoring and to provide further insight into parameter
values linked to reverse iontophoresis and reservoir formation.
6.2 Skin Analysis Techniques
Skin sampling provides potential for diagnosis of a number of local skin conditions
(such as eczema, psoriasis and cancer) and of diseases associated with internal
organs as well as detection of topical and systemic administered drugs [142]. There
are a number of ways in which skin sampling can be carried out. These can be
classified into three categories:
i) harvesting of epidermal constituents by minimally invasive methods, such as
reverse iontophoresis, electroporation, ultrasound or suction blisters[143];
ii) direct collection of skin tissue by punch or shave biopsy, followed by liquification
of the sample [144, 141]; and
iii) tape stripping.
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Figure 6-1: A schematic showing intact skin and three sampling techniques. BS,
blister skin; BF, blister fluid. Taken from [141]
i) Such minimally invasive methods include reverse iontophoresis which has been
the focus of much of this thesis. Electroporation uses pulses of high voltage
to increase skin permeability by opening pores, which is sometimes done in
conjunction with other transdermal delivery and sampling techniques including
iontophoresis [145]. Ultrasound works in a similar way; low frequency ultrasound
is used to produce micro-pores in the stratum corneum. In the suction blister
technique, blisters are artificially induced causing the epidermis to detach from the
underlying dermis. The induced blister then fills with fluid from the surrounding
tissue which is extracted with a syringe for analysis (Figure 6-1).
ii) A punch biopsy is taken by rotating a circular blade into the skin to the depth of
the sub-cutis to obtain a specimen which is lifted and cut from the site with scissors
(Figure 6-1). A shave biopsy is usually taken using a scalpel and samples the skin
to the depth of the dermis (Figure 6-1). Whilst these sampling techniques are
valuable in disease diagnosis, the invasive nature of biopsies limits routine clinical
adoption. Such skin sampling has been used post mortem in cases of overdose [146].
Post mortem data may prove valuable in determining the location and nature of
a drug reservoir in the skin but previous drug history of the individual is unlikely
to be known with any certainty.
iii) Tape stripping is comparatively quick and non-invasive. Though the practice
of tape stripping has been criticised for lack of standardised protocol [142], it is
the most practical way of collecting the whole reservoir ethically.
We therefore focus our efforts on verification of reverse iontophoresis via compar-
ison with tape stripping.
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6.3 Tape Stripping
One technique to take a sample from the SC is the use of appropriate adhesive
tape to ‘tape strip’ an area. This involves sequentially applying pieces of tape to
a chosen area of the skin and removing them to collect the surface layers of SC.
The SC is then removed from the tape using a solvent and these SC samples can
be tested for the presence of a given substance.
The amount of SC removed is typically determined by weighing the tape strips
before and after the strip process. Using the area of the tape and taking the density
of the SC as 1g/cm3 [147] the depth of the sample can be determined. Alternative
methods for determining depth of the SC removed, such as a colorimetric method,
are also available but due to cost weighing is typically used [148].
To quantify the presence of a specific substance in the sample the SC must first be
removed from the tape with a solvent. An appropriate assay is then carried out
for the chosen drug. The limit of quantification for many of these tests, however,
means that unless the concentration of drug present is sufficiently high the drug
may go undetected.
We are interested in relating the observed reservoir from tape strips to the actual
reservoir size in order to make inferences about systemic drug levels and therefore
drug dosage. We therefore want to determine how large a reservoir must be before
it is detectable and, if the selected drug is detected, how the amount of drug
retrieved relates to the reservoir size.
Assuming all drug in the stratum corneum (bound and unbound in the lipid and
aqueous domain) is collected on, and then removed from, tape during the tape
stripping process then, for a reservoir with distribution in the SC given by
C = Cu(x) + Cb(x),
we expect to retrieve ˆ L
L−d
Cdx ·A ·mr (6.1)
where A is the area sampled, to a depth d, mr is the molecular mass of the drug
and C is the reservoir concentration profile for bound + unbound drug. Therefore,
if we have a limit of quantification Q, in order to obtain a sufficient sample size
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We aim to discover if the values of unknown parameters such as faq, k7, D, γ and µ
could be determined through comparative tape stripping and reverse iontophoresis
results, and if so, which experiments would need to be carried out.
To give an idea of the kind of insight that comparison with tape stripping could
provide, we continue using the ‘theoretical drug’ discussed in Chapter 5. We
continue to consider the binding parameter sets 1-4 for Model 2, Table 5.2.
For the iontophoretic extraction we consider two values of faq with drug initially
distributed according to these values and with k7 = 0.1.
For ethical reasons tape stripping is usually carried out until the trans-epidermal
water loss (TEWL) reaches a critical value, at which point further tape stripping
may cause pain and more permanent damage to the skin [149]. This is usually
at about a depth of 75% of total SC depth. We assume that tape stripping
achieves complete extraction of the SC reservoir to this depth. Results given
are for a tape stripped area of 3.2cm2 so that the same area is sampled in both
reverse iontophoresis and tape stripping. Of course in practice a larger area
could be sampled to fulfil the requirement of equation (6.2) and then rescaled
for comparison.
Fully compliant case:
We begin by considering the fully compliant case. Figures 6-2 - 6-5 show the
results for binding parameter sets 1-4 respectively. The top sub-figure in each
figure shows the spatial reservoir at t = 30.5days for bound and unbound drug in
the SC for x ∈ [0, L], where L is the skin surface. The second sub figure gives the
predicted iontophoretic flux in each interval as would be observed experimentally.
The final sub-figure compares the total extraction (approximated to be all drug
extracted during the first hour) in each iontophoresis case and the extraction for
tape stripping.
From these results it can be seen that for scenarios where there is more bound
drug in the reservoir, tape stripping gives higher readings than both reverse
iontophoresis extractions, Figure 6-2. However, where the reservoir is made up
of mostly unbound drug, in the cases where faq=1, i.e. where all unbound drug
is available for extraction, predicted extraction by reverse iontophoresis is higher
than tape stripping. This could arise in two ways: as tape stripping only retrieves
drug in the surface 75% of the SC, and the whole unbound reservoir is retrieved
by reverse iontophoresis when faq = 1, then if the unbound reservoir is that much
larger than the bound reservoir then the extraction via reverse iontophoresis will
be higher. Alternatively, as the predicted extraction for reverse iontophoresis
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includes all drug extracted within the first hour, after the first 30 minute interval,
a significant amount of that is likely to come from the plasma.
We therefore construct the following dose regimen in which drug is administered for
23 days and then withdrawn for 7 days before extraction (on day 30). This allows a
reservoir to build up in the SC in days 1-23 and drug to clear from the plasma in the
last 7 days without depleting the reservoir completely. The plasma profile resulting
from this dose regimen is given in Figure 6-6. Then for each binding parameter set
1-4, we give in Figures 6-7 - 6-10, the predicted spatial reservoir 30.5 days after the
initial dose, along with the predicted reverse iontophoretic extraction for faq=0.1
and faq=1, and the predicted drug collected from tape stripping.
Most notable when considering the 7 day abstinence case, is the significant
reduction in reservoir size for the binding parameter sets 1 and 2, with high
diffusion in reservoir formation. In fact, the comparison of a fully compliant reading
to a 7 day placebo reading would provide a good idea of how quickly the reservoir
empties and therefore a measure of the potential for historic monitoring.
In Figure 6-8 (binding set 2) we again predict a higher reading for reverse
iontophoresis (when faq=1) than for tape stripping. As there is no drug extracted
from the plasma this result would indicate that, due to diffusion, the reservoir is
fairly evenly distributed in the SC and that a significant portion of it is unbound
and so the disparity comes from the fact that tape stripping only retrieves the
surface 75%. Comparing Figure 6-7 with 6-8, and Figure 6-9 with 6-10 it can be
seen that a bigger difference is observed between reverse iontophoresis and tape
stripping when the reservoir is mostly bound.
Comparison of tape stripping and reverse iontophoresis can give an estimate of
the percentage of the reservoir available for extraction by reverse iontophoresis.
This dosing regimen described provides an opportunity to view the reservoir
separately from the plasma. However, the experiments suggested by these
numerical simulations may be difficult to recreate in vivo for ethical reasons.
Moreover, the reservoir size is significantly reduced (especially when diffusion
is present) and so may not be detectable with procedures currently available.
An alternative solution would be to take the empty-reservoir extraction from a
drug-naive patient after a single dose and compare to a full-reservoir (compliant)
extraction of the same patient so that the drug concentration relating to reservoir
size could be identified.
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6.4 Conclusion
In this chapter we have provided comparative results for reverse iontophoresis and
tape stripping of the reservoir for two dose regimens for a range of parameter sets
for Models 2 and 3.
As both bound and unbound drug in the lipid and aqueous are collected via
tape stripping, it may appear to be a preferable extraction technique to reverse
iontophoresis. However, tape stripping can be a long, arduous procedure to prepare
for and process, and the experience can be uncomfortable for the patient. It is
therefore more likely that tape stripping could be used to provide a method to
identify parameters relating to the iontophoretic extraction.
We conclude that comparative tape stripping could provide valuable insight into
the nature of the reservoir; reverse iontophoresis is only able to extract drug
that is unbound and in the pathway of the current, whereas tape stripping is
able to extract the whole reservoir to a depth of 75% of the SC. We believe
the most valuable data would be for a situation where reservoir extraction via
reverse iontophoresis could be isolated from plasma extraction either by using
the compliance scenario described (which risks reservoir being too small) or by
taking the empty-reservoir extraction from a drug naive patient and comparing to
a full-reservoir (compliant) extraction of the same patient so that drug relating to
reservoir size could be identified.
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Figure 6-2: The predictions in this figure are for the fully compliant case using
binding parameter set 1 for Model 2. (Top) the predicted spatial reservoir at
t = 30.5days for the fully compliant case with binding parameter set 1, where L
is the skin surface. The vertical red line shows the depth of the tape stripping.
(Middle) Predicted iontophoretic extraction flux in each interval for faq=0.1 and
faq=1 with k7=0.1 and drug distributed according to faq at the beginning of
extraction. (Bottom) The extraction in the first hour of each iontophoresis case
and total extraction via tape stripping.
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Figure 6-3: The predictions in this figure are for the fully compliant case using
binding parameter set 2 for Model 2. (Top) the predicted spatial reservoir at
t = 30.5days for the fully compliant case with binding parameter set 2, where L
is the skin surface. The vertical red line shows the depth of the tape stripping.
(Middle) Predicted iontophoretic extraction flux in each interval for faq=0.1 and
faq=1 with k7=0.1 and drug distributed according to faq at the beginning of
extraction. (Bottom) The extraction in the first hour of each iontophoresis case
and total extraction via tape stripping.
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Figure 6-4: The predictions in this figure are for the fully compliant case using
binding parameter set 3 for Model 2. (Top) the predicted spatial reservoir at
t = 30.5days for the fully compliant case with binding parameter set 3, where L
is the skin surface. The vertical red line shows the depth of the tape stripping.
(Middle) Predicted iontophoretic extraction flux in each interval for faq=0.1 and
faq=1 with k7=0.1 and drug distributed according to faq at the beginning of
extraction. (Bottom) The extraction in the first hour of each iontophoresis case
and total extraction via tape stripping.
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Figure 6-5: The predictions in this figure are for the fully compliant case using
binding parameter set 4 for Model 2. (Top) the predicted spatial reservoir at
t = 30.5days for the fully compliant case with binding parameter set 4, where L
is the skin surface. The vertical red line shows the depth of the tape stripping.
(Middle) Predicted iontophoretic extraction flux in each interval for faq=0.1 and
faq=1 with k7=0.1 and drug distributed according to faq at the beginning of
extraction. (Bottom) The extraction in the first hour of each iontophoresis case
and total extraction via tape stripping.
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Figure 6-6: The predicted plasma profile for the drug regimen described, where
drug is administered for days 1-23 and then a placebo dose is given in the remaining
7 days.
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Figure 6-7: The predictions in this figure are for the drug regimen described,
where drug is administered for days 1-23 and then a placebo dose is given in
the remaining 7 days. Reservoir formation is predicted using binding parameter
set 1 for Model 2. (Top) the predicted spatial reservoir at t = 30.5days for the
fully compliant case with binding parameter set 1, where L is the skin surface.
The vertical red line shows the depth of the tape stripping. (Middle) Predicted
iontophoretic extraction flux in each interval for faq=0.1 and faq=1 with k7=0.1
and drug distributed according to faq at the beginning of extraction. (Bottom)
The extraction in the first hour of each iontophoresis case and total extraction via
tape stripping.
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Figure 6-8: The predictions in this figure are for the drug regimen described,
where drug is administered for days 1-23 and then a placebo dose is given in
the remaining 7 days. Reservoir formation is predicted using binding parameter
set 2 for Model 2. (Top) the predicted spatial reservoir at t = 30.5days for the
fully compliant case with binding parameter set 2, where L is the skin surface.
The vertical red line shows the depth of the tape stripping. (Middle) Predicted
iontophoretic extraction flux in each interval for faq=0.1 and faq=1 with k7=0.1
and drug distributed according to faq at the beginning of extraction. (Bottom)
The extraction in the first hour of each iontophoresis case and total extraction via
tape stripping.
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Figure 6-9: The predictions in this figure are for the drug regimen described,
where drug is administered for days 1-23 and then a placebo dose is given in
the remaining 7 days. Reservoir formation is predicted using binding parameter
set 3 for Model 2. (Top) the predicted spatial reservoir at t = 30.5days for the
fully compliant case with binding parameter set 3, where L is the skin surface.
The vertical red line shows the depth of the tape stripping. (Middle) Predicted
iontophoretic extraction flux in each interval for faq=0.1 and faq=1 with k7=0.1
and drug distributed according to faq at the beginning of extraction. (Bottom)
The extraction in the first hour of each iontophoresis case and total extraction via
tape stripping.
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Figure 6-10: The predictions in this figure are for the drug regimen described,
where drug is administered for days 1-23 and then a placebo dose is given in
the remaining 7 days. Reservoir formation is predicted using binding parameter
set 4 for Model 2. (Top) the predicted spatial reservoir at t = 30.5days for the
fully compliant case with binding parameter set 4, where L is the skin surface.
The vertical red line shows the depth of the tape stripping. (Middle) Predicted
iontophoretic extraction flux in each interval for faq=0.1 and faq=1 with k7=0.1
and drug distributed according to faq at the beginning of extraction. (Bottom)





In Chapter 2, Model 1 was constructed using buprenorphine as a case study.
A three compartment model of systemic drug concentration was developed
comprising of three compartments; plasma, rapidly perfused tissues and slowly
perfused tissues. The model acts as a structural example for the type of
mechanistic, customisable-dose model that could be used with the full model
system.
In Chapter 3 a full description of the skin structure and homoeostasis is provided
and existing modelling approaches for passive transdermal delivery are reviewed.
Building on these ideas we create a one dimensional spatial model of the SC which
includes desquamation, binding and unbinding, and diffusion of the unbound drug
in the SC. Results from the model exploration highlight the importance of binding
within the SC as a mechanism for reservoir ‘storage’. This supports other recent
research in the literature which identifies binding as an important factor when
considering passive movement across the SC [92]. The model lends itself well to
the exploration of non-invasive extraction and drug monitoring techniques across
the skin as it describes both total amount in the SC and also spatial distribution
of drug in the SC. The first measure is relevant to extraction techniques such as
reverse iontophoresis, whilst the second lends itself to the process of tape stripping.
In Chapter 4 a one dimensional SC model is created which divides the SC
into a lipid and aqueous domain, as described by Imanidis and Luetolf in
their iontophoretic delivery model [120]. All three mechanisms of movement;
electromigration, electroosmosis and passive diffusion are considered for reverse
iontophoretic transport, with electromigration assumed to provide the largest
contribution based on research in the literature. Distribution of the reservoir
between lipid and aqueous domains for reverse iontophoresis was shown to be an
important factor for interpreting the results from iontophoresis, as drug in the lipid
takes longer to be extracted as it must move into the aqueous domain first. One
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of the key difficulties for modelling reverse iontophoresis is that exact lag time is
unknown which means that drug that is extracted from the reservoir is not easily
identified.
In Chapter 5 the work from the previous chapters is combined to provide a full
model system describing drug administration to extraction. We created a simplified
model for the drug lithium to compare to reverse iontophoresis data. A good fit is
obtained after using any one of three model corrections: an adjustment to velocity
associated with electromigration; an increased tortuosity of extraction path-length;
or re-inclusion of the lipid aqueous domain division.
In Chapter 5, as in Chapter 3, it is shown that when the diffusion coefficient for
reservoir formation is large, the historical nature of the reservoir is minimised. This
is because diffusion causes the reservoir to quickly reach equilibrium with plasma
concentrations. Therefore, when seeking a drug suited to skin monitoring, a drug
with small diffusion coefficient is likely to be preferred. This has to be balanced
with a requirement for high drug mobility, so that drug can be extracted via reverse
iontophoresis. Analysis of the full model in Chapter 5 shows that diffusion has a
much larger impact on reservoir size when drug is able to bind in the SC and that,
whilst binding results in a larger overall reservoir size (bound + unbound), the size
of the unbound reservoir is more influenced by the size of the diffusion coefficient.
Four compliance scenarios were chosen to see if skin monitoring could provide
further compliance insight than blood sampling alone. The compliance scenarios
were chosen so that pairs of different pairs of them would provide the same plasma
concentration despite a difference in the number of doses taken. We found that
distinction in extraction profiles between the various compliance scenarios was
most clearly observed in the case where there was no diffusion during reservoir
formation, the reservoir was mainly unbound, and mainly located in the aqueous
domain. The research in Chapter 5 demonstrates the potential for drug presence
in the skin to determine patient compliance to a drug regimen.
In Chapter 6 numerical simulations for tape stripping were presented for the fully
compliant daily dose regimen and for a regimen which is devised to allow presence
of a reservoir with near-zero plasma concentration, such that the reservoir is
identifiable from RI predictions. Comparing the reverse iontophoresis reservoir
with tape stripping predictions provides information about how much of the total
reservoir is available for extraction i.e. how much of it is unbound and in the
aqueous domain. As the tape stripping only takes the top 75% of the SC, using
the drug regimen devised, the distribution of the reservoir across the depth of the




With additional availability of experimental data, the models can be further
validated to establish their capabilities and limitations with increasing resolution.
Specifically, the data required for the next stage of development should include
(but is not limited to):
• continuous extraction data / shorter sampling intervals for reverse ionto-
phoresis;
• estimates for binding within the stratum corneum (for the drug / drugs under
scrutiny); and
• multiple sources of data from the same patient using alternative methods,
i.e. tape stripping and reverse iontophoresis
The collection of new data opens up the possibility to investigate inter-patient
variability, this is a necessary step in validating reverse iontophoresis as a historical
drug monitoring technique.
The focus of the present study has been on lipophilic drugs. The reservoir
formation model could be adapted for hydrophilic drugs by considering alternative
routes through the stratum corneum. The transcellular pathway could be
incorporated using a trapping and release method as used by Mollee and Bracken
for an intercellular approximation [64], described in Chapter 3.
It is not fully understood where the drug in the SC resides as techniques involve
breaking down the SC structure when sampling. However if this information
becomes available in the future, stochastic cell based models may provide useful
insight into reservoir formation.
The resistance of the SC changes on application of a current, this is thought
to be caused by the opening of porous pathways. This was accounted for in
part, in Chapter 5, by assuming that the drug reservoir is outside of the aqueous
domain (porous pathway) prior to the start of reverse iontophoresis. As reservoir
is mainly extracted during the first intervals of iontophoresis, the transient nature
of resistance and therefore extraction in these early periods warrants further
investigation.
It has been shown that ionisation and pH affects iontophoretic delivery for weak
electrolytes. pH effects could be incorporated into the extraction model to
identify further characteristics of a drug that would be well suited for compliance
monitoring via the skin.
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CHAPTER 7. CONCLUSIONS
This thesis provides a novel mathematical framework from which the exploration
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